ChemLifeIntel
Access
CLINICAL & PIPELINEDrug ApprovalNotable

Sanofi Aventis US Secures Latest FDA Labeling Approval for AUBAGIO (Teriflunomide)

MK
Meera KrishnanView Profile →
Senior Regulatory Intelligence Analyst
EXECUTIVE SUMMARY

Sanofi Aventis US recently secured FDA approval for a supplemental labeling update (SUPPL 18) for its oral drug, AUBAGIO (teriflunomide), on February 11, 2026. This marks another step in the product's lifecycle management since its original New Molecular Entity approval in 2012, impacting regulatory compliance and commercial strategy for procurement and supply chain leaders.

Approval Summary: Latest FDA Labeling Update for Sanofi Aventis US's Teriflunomide (AUBAGIO)

On February 11, 2026, Sanofi Aventis US, through its manufacturer Genzyme Corporation, received a standard review approval from the U.S. Food and Drug Administration (FDA) for a supplemental application (SUPPL 18) concerning the labeling of its oral drug, AUBAGIO (teriflunomide). This latest approval for NDA202992 follows the original Type 1 New Molecular Entity (NME) approval granted on September 12, 2012. The updated label, dated February 18, 2026, along with a revised Medication Guide dated February 11, 2026, signifies a refinement in the product's prescribing information. For procurement directors and supply chain VPs, this necessitates an immediate review of all existing product documentation, packaging, and distribution protocols. Ensuring that all materials reflect the most current FDA-approved label is critical for maintaining regulatory compliance and avoiding potential market disruptions or penalties. Regulatory affairs heads must promptly disseminate these updates across their organizations to ensure all promotional and educational materials align with the new specifications, safeguarding the product's market integrity.

Regulatory Trajectory: A Decade of FDA Engagement for Teriflunomide (AUBAGIO)

The approval of supplemental application 18 for AUBAGIO (teriflunomide) is part of a long and active regulatory history for Sanofi Aventis US, with NDA202992 accumulating 18 supplemental approvals since its initial NME designation in 2012. This trajectory includes significant efficacy updates, such as SUPPL 1 approved on October 17, 2014, SUPPL 6 on July 24, 2019, and SUPPL 13 on April 30, 2021, alongside numerous labeling adjustments in 2016, 2017, 2019, 2020, 2021, and 2024. This sustained engagement with the FDA underscores Sanofi Aventis US's commitment to continuous product lifecycle management and optimization. For business development executives, this pattern indicates a strategy focused on maximizing the product's value and market longevity through ongoing clinical data integration and regulatory refinement. Regulatory affairs heads must recognize that such an active regulatory profile demands a highly agile and responsive compliance framework, capable of rapidly adapting to frequent updates to maintain market authorization and competitive positioning for AUBAGIO in the United States.

Commercial Implications of AUBAGIO's Evolving Product Labeling

The continuous stream of labeling updates for AUBAGIO (teriflunomide), including the latest approval on February 11, 2026, carries direct commercial implications for Sanofi Aventis US. While the specific nature of this particular labeling change is not detailed, such updates often involve refinements to dosage, administration instructions, safety warnings, or patient selection criteria. These modifications can influence prescribing patterns, physician confidence, and patient adherence, thereby impacting market uptake and revenue streams. The drug's oral route of administration, as specified in the product information, remains a key differentiator in its therapeutic class. For procurement directors, these evolving labels necessitate vigilance in managing inventory and packaging, ensuring that all distributed products conform to the latest regulatory standards. Supply chain VPs must implement robust version control systems for packaging inserts and patient information leaflets to prevent the distribution of outdated materials, which could lead to costly recalls or regulatory sanctions, directly affecting profitability and brand reputation.

Supply Chain Resilience: Manufacturing and Sourcing for Teriflunomide

The manufacturing of AUBAGIO (teriflunomide) is attributed to Genzyme Corporation, as indicated in the application details for NDA202992. The absence of information regarding alternative suppliers within the available knowledge graph highlights a critical consideration for supply chain resilience. Relying on a single named manufacturer for a key pharmaceutical product like teriflunomide introduces inherent risks related to production capacity, quality control, and potential disruptions from geopolitical events or natural disasters. For procurement directors, this necessitates a comprehensive risk assessment of Genzyme Corporation's manufacturing sites and supply chain robustness. Developing robust contingency plans, including strategic inventory buffering and exploring potential secondary sourcing options, becomes paramount. Supply chain VPs must prioritize strong supplier relationship management with Genzyme Corporation to ensure transparency, secure supply agreements, and proactively address any potential vulnerabilities to safeguard the uninterrupted availability of AUBAGIO in the market.

Strategic Outlook: Maintaining Market Presence Through Regulatory Compliance for Sanofi Aventis US

The ongoing regulatory activity surrounding AUBAGIO (teriflunomide), culminating in the recent labeling approval on February 11, 2026, underscores the strategic importance of continuous regulatory compliance for Sanofi Aventis US. With 18 supplemental approvals for NDA202992 since its original NME designation, maintaining an up-to-date regulatory posture is not merely a compliance exercise but a critical component of sustaining market presence and competitive advantage. For regulatory affairs heads, this means investing in advanced regulatory intelligence systems and highly skilled personnel capable of interpreting and implementing complex label changes swiftly. Business development executives should view these continuous updates as opportunities to refine product messaging and market positioning, leveraging the latest clinical and safety information. Procurement and supply chain leaders must ensure their operational frameworks are agile enough to adapt to these regulatory shifts, thereby protecting product availability and market integrity for Sanofi Aventis US in the long term.

ChemLifeIntel analysis · Meera Krishnan. Compiled from primary and reported sources.
CHEMLIFEINTEL TERMINAL

Go deeper than the brief

The Terminal adds the full entity graph behind this story — downstream buyer-exposure mapping, alternative-supplier shortlists, 5-year compliance footprints and live supply-chain risk scores. Built for procurement, regulatory and business-development teams.

TERMINAL ACCESS
Request Terminal Access

Tell us where to send your access details — used by procurement and regulatory teams at 40+ pharmaceutical companies.

Used by procurement and regulatory teams at 40+ pharmaceutical companies
CONNECTED COVERAGE

Related Intelligence

REGULATORY INTELLIGENCE
6h ago

SonoThera Secures $125M Series B Funding: No FDA Import Alert Information Available

The provided source text details SonoThera's successful $125 million Series B funding round, backed by major pharma entities. Crucially, the source contains no information regarding any FDA Import Alert, regulatory action, facility issues, or product detentions, making an analysis of such an event impossible based on the given data.

REGULATORY INTELLIGENCE
6h ago

FDA Class II Recall: Essential Wellness Pharma's Progesterone Injection Fails Sterility Assurance

Kalman Health & Wellness, Inc. dba Essential Wellness Pharma initiated a Class II recall for its Progesterone 100 mg/mL in Corn Oil Injection due to a critical lack of sterility assurance. This 2015 nationwide recall, terminated in 2017, stemmed from poor sterile production practices at its Peoria, IL facility. For procurement and regulatory leaders, this highlights the severe risks associated with compounded sterile preparations and underscores the imperative for rigorous supplier qualification and ongoing oversight in this sector.

CLINICAL & PIPELINE
6h ago

Trump Administration Floats Permanent Medicare Drug Price Negotiation Framework

The Trump administration proposes a permanent framework for Medicare drug price negotiations, leveraging the Inflation Reduction Act. This signals enduring pressure on pharmaceutical pricing, necessitating proactive strategic adjustments for procurement, regulatory affairs, and business development executives to mitigate revenue impacts and ensure market access.

CLINICAL & PIPELINE
6h ago

India's CDSCO Updates COVID-19 Vaccine Approvals Amidst Key Regulatory Shifts for Animal Health and GLP-1 Drugs

India's regulatory authority has updated its list of approved COVID-19 vaccines as of April 22, 2026, signaling ongoing public health oversight. Concurrently, new prohibitions on Chloramphenicol and Nitrofurans in food-producing animals, alongside strengthened enforcement for GLP-1 based drugs, underscore a tightening regulatory environment. Businesses must adapt supply chains and compliance strategies to these evolving mandates.

CLINICAL & PIPELINE
6h ago

Akeso Initiates Phase Ib/II Trial for AK138D1 in Advanced Breast Cancer, Signaling ADC Pipeline Expansion

Akeso has initiated a Phase Ib/II trial (AK138D1-202) for its HER3-targeting ADC, AK138D1, in advanced breast cancer, including HR+/HER2- and triple-negative subtypes. This early-stage development signals Akeso's strategic focus on novel oncology mechanisms, potentially impacting future procurement strategies for advanced biologics and competitive dynamics in the breast cancer therapeutic landscape. Decision-makers should monitor trial progression for market entry implications.

CLINICAL & PIPELINE
6h ago

Sun Pharma Canada Secures FDA Approval for Generic Clobetasol Propionate Spray: Market Impact and Procurement Shifts

Sun Pharma Canada has received FDA approval for its generic Clobetasol Propionate 0.05% Topical Spray (ANDA208842) on March 26, 2018. This development introduces a new therapeutically equivalent option into the market, intensifying competition for existing suppliers. Procurement directors and supply chain VPs must now re-evaluate sourcing strategies to capitalize on potential cost efficiencies and enhance supply chain resilience.

CLINICAL & PIPELINE
6h ago

Torrent Pharmaceuticals Secures US FDA ANDA Approval for Generic Lenalidomide Capsules, Reshaping Market Dynamics

Torrent Pharmaceuticals has received US FDA approval for its generic Lenalidomide capsules (ANDA213405). This significant development introduces a new competitor for a critical oncology molecule, offering procurement directors opportunities for cost reduction and supply chain diversification. Regulatory affairs and business development teams must assess the implications of this market entry, particularly concerning the existing REMS program.

TRADE & SUPPLY CHAIN
6h ago

FDA Reports Widespread Drug Shortages and Discontinuations Impacting Critical Care, Oncology, and CNS Therapies

The FDA's latest report reveals extensive drug shortages and discontinuations across critical therapeutic areas, including oncology, critical care, and CNS. This necessitates immediate strategic adjustments for procurement directors and supply chain VPs to mitigate supply chain vulnerabilities, manage pricing volatility, and ensure patient access to essential medications amidst a complex regulatory landscape.

REGULATORY INTELLIGENCE
6h ago

CDSCO Intensifies Regulatory Scrutiny: Implications for India's Pharma and MedTech Supply Chains

CDSCO's recent flurry of alerts, including drug theft, falsified medicines, and product recalls, signals heightened regulatory vigilance across India's pharmaceutical and medical device sectors. This demands robust supply chain security, stringent quality controls, and agile regulatory compliance from global and domestic players. Procurement, regulatory, and supply chain leaders must proactively adapt to mitigate risks and ensure market access.

REGULATORY INTELLIGENCE
7h ago

FDA Hearing Puts Amgen's Tavneos Market Future at Risk Amid Independent Data Review

Amgen faces a critical FDA hearing for its rare disease treatment, Tavneos, following an independent data review. This event could lead to market removal, demanding immediate risk assessment for procurement, supply chain, and regulatory teams. It underscores the FDA's intensified scrutiny on post-market data integrity and product efficacy.

REGULATORY INTELLIGENCE
7h ago

Takeda's TYK2 Inhibitor Victory Reshapes Plaque Psoriasis Market Dynamics

Takeda has secured a significant competitive advantage in the TYK2 inhibitor landscape, outperforming Bristol Myers Squibb’s Sotyktu. This victory positions Takeda strongly for its anticipated plaque psoriasis launch next year, signaling a material shift in market share and procurement strategies for dermatology portfolios. Decision-makers must reassess existing supply agreements and future market entrants.

REGULATORY INTELLIGENCE
8h ago

Genentech Restructures gRED Leadership, Signals R&D Strategic Shift

Genentech, a Roche subsidiary, is undergoing a significant restructuring within its Research and Early Development (gRED) group in South San Francisco, affecting key Vice Presidents. This move signals a strategic re-evaluation of early-stage pipeline priorities, impacting future drug development and commercial opportunities for biopharma stakeholders. The total number of affected positions remains undisclosed.

REGULATORY INTELLIGENCE
8h ago

Teva Pharmaceuticals Restructures API Unit: 250 Layoffs and Divestiture Signals Strategic Pivot

Teva Pharmaceuticals is implementing significant restructuring, including 250 layoffs at its Neot Hovav, Israel API unit, TAPI, as it seeks a buyer. This divestiture, part of a broader $700 million savings initiative, signals Teva's strategic pivot towards innovative brands like Austedo and Ajovy. Supply chain and procurement leaders must assess potential API sourcing shifts and geopolitical risks impacting Teva's operational stability and future supply agreements.

CLINICAL & PIPELINE
8h ago

EU Nations Push for Unified Drug Pricing Strategy Amid US Pressure: Key Implications for Pharma

Belgium, Netherlands, Luxembourg, Austria, and Ireland's June 10 statement signals a coordinated EU response to drug pricing pressure from the U.S. This move demands immediate attention from procurement directors and regulatory affairs heads, indicating potential shifts towards unified European pharmaceutical procurement and market access frameworks, impacting future commercial strategies across the Union.

REGULATORY INTELLIGENCE
8h ago

Astellas Implements $1.3 Billion Cost-Savings Program Ahead of Xtandi Patent Cliff

Astellas is implementing a 200 billion yen ($1.3 billion) cost-savings program over five years to mitigate a projected $6 billion revenue decline from its prostate cancer drug Xtandi's patent expiration. This strategic initiative, as stated by CEO Naoki Okamura, extends beyond mere cost or headcount reductions, signaling a broader operational recalibration for the global pharmaceutical firm.

REGULATORY INTELLIGENCE
2020-12-30

Fresenius Kabi's Sensorcaine-MPF Recall: Subpotent Epinephrine Exposes Critical Quality Control Gaps

Fresenius Kabi USA, LLC initiated a Class II recall for 4411 trays of Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) due to subpotent epinephrine. This nationwide recall, D-0172-2021, highlights critical quality control failures impacting patient safety and supply chain reliability. Procurement directors must assess supplier quality systems, while regulatory affairs heads should monitor Fresenius Kabi's remediation efforts to mitigate future supply disruptions.

REGULATORY INTELLIGENCE
2020-12-30

Akebia Therapeutics' Auryxia (Ferric Citrate) Recall Signals Persistent CGMP Compliance Risks

Akebia Therapeutics initiated a Class II voluntary recall of 2,170 bottles of Auryxia (ferric citrate) tablets, 210 mg, Lot 9062, due to CGMP Deviations. This nationwide distribution event, terminated September 1, 2021, underscores persistent quality control challenges in pharmaceutical manufacturing. Procurement and regulatory teams must enhance supplier vigilance and supply chain resilience against such compliance risks.

REGULATORY INTELLIGENCE
2020-12-23

Zydus Pharmaceuticals' Lansoprazole Recall: Dissolution Failures Expose Generic Drug Supply Chain Vulnerabilities

Zydus Pharmaceuticals USA Inc. initiated a Class II voluntary recall of 15,144 cartons of Lansoprazole Delayed-Release Orally Disintegrating Tablets 15 mg due to failed dissolution specifications. This event, now terminated, underscores critical quality control challenges in generic drug manufacturing. Procurement and regulatory teams must scrutinize supplier quality systems, particularly for distributed products, to mitigate supply chain disruptions and ensure patient safety and market compliance.

REGULATORY INTELLIGENCE
2020-12-23

Advanced Nutriceuticals Recalls BPC-157 Due to Critical Sterility Assurance Lapses

Advanced Nutriceuticals, LLC has initiated a Class II recall for BPC-157 vials due to a critical lack of sterility assurance in its production processes. This voluntary action impacts multiple lots distributed across seven U.S. states, underscoring significant quality control deficiencies. Procurement and regulatory teams must scrutinize supplier qualification and aseptic manufacturing protocols to mitigate similar supply chain risks.

REGULATORY INTELLIGENCE
2020-12-23

Taro Pharmaceuticals Recalls Kroger Clotrimazole Cream Due to Degradation Impurity

Taro Pharmaceuticals U.S.A., Inc. initiated a Class II recall for 133,452 tubes of Kroger Athlete's Foot Cream (Clotrimazole Cream USP, 1%) due to an unknown degradation impurity exceeding specification limits. This voluntary, firm-initiated recall, distributed nationwide in the USA and Canada, highlights critical quality control challenges for over-the-counter antifungal products. The recall, D-0154-2021, was terminated on February 21, 2024.

REGULATORY INTELLIGENCE
2020-12-23

Biogen's Vumerity Recall: Dissolution Failures Highlight Critical Pharmaceutical Quality Control Risks

Biogen Inc. initiated a Class II recall for 5,307 bottles of Vumerity (diroximel fumarate) due to failed dissolution specifications. This event, terminated by the FDA, underscores the persistent quality control challenges in pharmaceutical manufacturing. Procurement and regulatory teams must scrutinize supplier quality systems to mitigate supply chain disruptions and ensure product efficacy for patients.

REGULATORY INTELLIGENCE
2020-12-23

AVKARE Inc. Faces Class I Recall for Trazodone-Sildenafil Mix-up at Third-Party Facility

AVKARE Inc. initiated a Class I recall for 14,368 bottles of TraZODONE Hydrochloride Tablets 100 mg due to an inadvertent sildenafil mix-up at a third-party facility. This event underscores critical vulnerabilities in outsourced manufacturing and demands immediate attention from procurement and regulatory leaders to reassess quality control and supply chain resilience.

REGULATORY INTELLIGENCE
2020-12-23

Simex Logistics' Class II Recall: Subpotent Hand Sanitizer Exposes Supply Chain Vulnerabilities

Simex Logistics SA de CV initiated a Class II recall of 1,800 bottles of CitruGel Hand Sanitizer due to subpotency, impacting US states. This event underscores critical quality control gaps in international supply chains, demanding heightened vigilance from procurement and regulatory teams. The recall, terminated in 2023, highlights persistent challenges in ensuring product efficacy from overseas manufacturers.

REGULATORY INTELLIGENCE
2020-12-16

Asiaticon Hand Sanitizer Recall: CGMP Failures Highlight International Sourcing Risks

Asiaticon, SA de CV's V-Klean Hand Sanitizer Gel Alcohol 70% faced a Class II recall (D-0116-2021) due to critical Current Good Manufacturing Practices (CGMPs) deficiencies at its Ciudad De Mexico facility. This voluntary recall, involving 111,500 units distributed in Texas, underscores the persistent regulatory risks associated with outsourced manufacturing of over-the-counter (OTC) products. Procurement and regulatory teams must intensify supplier qualification and oversight, particularly for international partners, to mitigate supply chain disruptions and ensure product quality.

CLINICAL & PIPELINE
2020-12-16

TEVA PHARMS USA Gains FDA Approval for Generic EFINACONAZOLE 10% Topical Solution, Reshaping Antifungal Market Dynamics

TEVA PHARMS USA has secured FDA approval for its generic EFINACONAZOLE 10% topical solution (ANDA211827) on December 16, 2020. This approval introduces a therapeutically equivalent alternative, intensifying competition in the antifungal market. Procurement directors should evaluate TEVA as a new supplier, while supply chain VPs must anticipate potential price erosion and adjust sourcing strategies for this key molecule.

REGULATORY INTELLIGENCE
2020-12-16

Novocol Pharmaceutical's Mepivacaine Hydrochloride Recall: Label Mix-Up Exposes Critical Supply Chain Vulnerabilities

Novocol Pharmaceutical of Canada, Inc. initiated a Class III recall of 15,398 cartridges of Scandonest 3% Plain (Mepivacaine Hydrochloride) due to a label mix-up. This voluntary action, impacting U.S. distribution, underscores critical quality control vulnerabilities for procurement and regulatory teams. The terminated recall highlights the imperative for robust supplier oversight and stringent labeling verification to mitigate supply chain disruption and patient safety risks.

REGULATORY INTELLIGENCE
2020-12-16

Shilpa Medicare Azacitidine Recall: CGMP Deviations Highlight Critical India-US Supply Chain Risks

Shilpa Medicare Limited initiated a Class II recall of 35,931 vials of Azacitidine for Injection due to CGMP deviations at its Polepally, India facility. This event, distributed by Armas Pharmaceuticals Inc. in the U.S., underscores critical supply chain vulnerabilities for essential oncology drugs. Procurement and regulatory teams must scrutinize supplier quality systems and diversify sourcing to mitigate disruption and ensure patient safety.

CLINICAL & PIPELINE
2020-12-15

RISING Secures FDA Approval for Sevelamer Hydrochloride Generic, Marketing Status Discontinued

RISING secured FDA approval on December 15, 2020, for its Abbreviated New Drug Application (ANDA) for Sevelamer Hydrochloride 400mg and 800mg tablets. Despite this regulatory milestone, the marketing status for both approved products is listed as "Discontinued." This indicates RISING is not actively marketing these generic Sevelamer Hydrochloride formulations, impacting immediate market competition and procurement strategies for this phosphate binder.

REGULATORY INTELLIGENCE
2020-12-09

FDA Class I Recall: Torrent Pharmaceuticals' Anagrelide Capsules Fail Dissolution, Triggering Supply Chain Review

Torrent Pharmaceuticals Limited's Class I recall of Anagrelide Capsules due to failed dissolution specifications underscores critical supply chain and regulatory risks. This event, impacting 2,496 bottles nationwide, necessitates immediate review of sourcing strategies for essential medicines. Procurement and regulatory leaders must assess supplier quality systems and diversify supply to mitigate future disruptions and ensure patient safety.

REGULATORY INTELLIGENCE
2020-12-09

Golden State Medical Supply's Aripiprazole Recall: Dissolution Failures Expose Quality Control Gaps

Golden State Medical Supply Inc. initiated a Class II nationwide recall of 11,922 bottles of Aripiprazole Tablets, 15 mg, due to failed dissolution specifications. This event, stemming from a critical quality control lapse, underscores the imperative for robust supplier qualification and stringent in-process testing for pharmaceutical packagers. Procurement and regulatory teams must reassess their due diligence protocols to mitigate similar supply chain risks.

REGULATORY INTELLIGENCE
2020-12-02

Heritage Pharmaceuticals' Felodipine Recall: Impurity Failures Highlight Global Supply Chain Risks

Heritage Pharmaceuticals Inc. initiated a Class III recall for Felodipine Extended Release Tablets due to out-of-specification impurity levels of Felodipine Related compound A. This voluntary, nationwide recall, now terminated, highlights critical quality control vulnerabilities for pharmaceutical distributors sourcing from overseas manufacturers. Procurement and regulatory teams must scrutinize supplier quality systems, especially for products manufactured in India, to mitigate supply chain disruption and ensure patient safety.

REGULATORY INTELLIGENCE
2020-12-02

AA PRODUCTS INC Recalls SYP Health Hand Sanitizer Due to Methanol Contamination and Subpotency

AA PRODUCTS INC initiated a Class II recall for SYP Health Hand Sanitizer Alcohol Gel (ethyl alcohol) 70% due to manufacturing at a facility that produced subpotent and methanol-contaminated product. This event highlights critical CGMP deviations, necessitating enhanced due diligence for procurement and regulatory teams to ensure product safety and efficacy in the supply chain.

REGULATORY INTELLIGENCE
2020-12-02

Jubilant Cadista's clomiPRAMINE Recall: Implications for Psychiatric Drug Supply Chain Integrity

Jubilant Cadista Pharmaceuticals, Inc. faced a Class II FDA recall for 4,416 bottles of clomiPRAMINE Hydrochloride Capsules, 50 mg, due to failed tablet/capsule specifications. This voluntary, firm-initiated action, terminated in March 2022, underscores critical quality control vulnerabilities. Procurement directors must enhance supplier oversight and diversify sourcing for essential psychiatric medications to mitigate supply chain disruptions and ensure patient safety.

REGULATORY INTELLIGENCE
2020-12-02

EYWA PHARMA INC Levetiracetam Recall: Critical Foreign Tablet Contamination Exposes Supply Chain Vulnerabilities

EYWA PHARMA INC initiated a Class II recall (D-0109-2021) for 5,451 bottles of Levetiracetam Tablets, USP 500 mg, due to 1000 mg tablets found in 500 mg bottles. This critical quality control failure, originating from Indian manufacturer VKT Pharma, underscores significant supply chain risks for procurement and regulatory teams. The recall, initiated November 2020, was terminated October 2024, indicating resolution but demanding continued vigilance.

REGULATORY INTELLIGENCE
2020-12-02

FDA Terminates Fusion Health and Vitality LLC Recall for Unapproved Immune Boost Drug Claims

The FDA has terminated a Class II recall initiated by Fusion Health and Vitality LLC for its Immune Boost product, marketed with unapproved drug claims. This highlights critical regulatory compliance risks for companies operating in the dietary supplement space, underscoring the necessity for rigorous adherence to NDA/ANDA requirements to avoid market disruptions and reputational damage.

REGULATORY INTELLIGENCE
2020-11-25

Milbar Laboratories' Benzoyl Peroxide Wash Recalled Globally Due to GMP Deviations

Milbar Laboratories, Inc. initiated a Class II recall of 7,591 bottles of DCL B Prox10 Anti-Blemish Wash (Benzoyl Peroxide 10%) due to GMP deviations. This voluntary action, impacting global distribution, underscores critical supply chain and regulatory risks. Procurement and regulatory teams must scrutinize supplier quality systems to mitigate similar disruptions and ensure product integrity.

REGULATORY INTELLIGENCE
2020-11-25

Preferred Pharmaceuticals Recalls Metformin HCl ER 500 mg Due to NDMA Contamination and CGMP Deviations

Preferred Pharmaceuticals, Inc. initiated a Class II recall of Metformin HCl Extended Release Tablets USP 500 mg due to N-Nitrosodimethylamine (NDMA) levels exceeding acceptable limits, stemming from CGMP deviations. This event, now terminated, underscores persistent nitrosamine risks in generic drug supply chains. Procurement and regulatory teams must enhance supplier scrutiny and impurity testing protocols.

REGULATORY INTELLIGENCE
2020-11-25

Albek De Mexico Faces Severe FDA Scrutiny Over Methanol Contamination in Hand Sanitizers

Albek De Mexico S.A. De C.V. initiated a nationwide Class II recall (D-0080-2021) for hand sanitizers due to critical CGMP deviations, including methanol contamination and sub-potent ethanol levels. This event highlights severe quality control failures at their San Juan Del Rio, Mexico facility, posing significant supply chain and regulatory risks for procurement directors and regulatory affairs heads sourcing from the region.

REGULATORY INTELLIGENCE
2020-11-25

Grato Holdings Recalls Homeopathic Energy Catalyst Over Undeclared API and Formulation Errors

Grato Holdings, Inc. initiated a Class III recall of 399 bottles of its Homeopathic Energy Catalyst due to an undeclared active pharmaceutical ingredient (API) and incorrect formulation. This event, terminated in October 2022, underscores critical quality control failures. Procurement and regulatory teams must enhance supplier vigilance to prevent similar integrity breaches and ensure compliance across all product categories.

REGULATORY INTELLIGENCE
2020-11-25

Milbar Laboratories' Salicylic Acid Pads Recall Signals Persistent GMP Challenges for OTC Drug Manufacturers

Milbar Laboratories, Inc. initiated a Class II recall (D-0093-2021) for 2,638 jars of Willa Pore Perfector (Salicylic Acid 2%) pads due to GMP deviations. This event, now terminated, underscores critical quality control vulnerabilities in OTC drug manufacturing and global supply chains. Procurement and regulatory teams must scrutinize supplier compliance to mitigate similar disruptions and ensure product integrity.

CLINICAL & PIPELINE
2020-11-19

Sandoz Inc. Secures Tentative FDA Approval for Generic ANDA 210481

Sandoz Inc. has received a Tentative Approval from the FDA for its Abbreviated New Drug Application (ANDA210481) on November 19, 2020. This signifies the generic drug meets all regulatory standards but cannot launch until reference product patents expire. This event signals future market competition and requires proactive monitoring by procurement and supply chain leaders for impending shifts in sourcing and pricing dynamics.

REGULATORY INTELLIGENCE
2020-11-18

H & H Remedies' Vapor Ointment Recall Highlights Enduring CGMP Compliance Risks for OTC Manufacturers

H & H Remedies, LLC's Class II recall of Vapor Ointment due to CGMP deviations underscores persistent quality control challenges in the OTC sector. Procurement and regulatory teams must enhance supplier qualification and audit programs to mitigate risks, ensuring product integrity and uninterrupted supply. This event, terminated in May 2024, serves as a critical reminder for vigilance.

REGULATORY INTELLIGENCE
2020-11-11

Marksans Pharma's Metformin Recall: NDMA Contamination Exposes Supply Chain Vulnerabilities for US Buyers

Marksans Pharma Limited initiated a Class II recall of Metformin Hydrochloride Extended-Release Tablets due to N-Nitrosodimethylamine (NDMA) impurity exceeding acceptable limits, stemming from CGMP deviations at its Goa, India facility. This nationwide recall, now terminated, underscores critical quality control challenges for procurement directors and regulatory affairs heads, demanding enhanced due diligence for pharmaceutical sourcing from India.

REGULATORY INTELLIGENCE
2020-11-04

Jarrow Formulas N-A-C Recall: FDA Class II Mislabelling Exposes Supply Chain Vulnerabilities

Jarrow Formulas Inc initiated a Class II voluntary recall of 533 units of N-A-C (N-Acetyl-L-Cysteine) 500 mg capsules due to mislabeling with N-A-C Sustain 600 mg tablets. This event, now terminated, underscores critical supply chain and regulatory risks for procurement and quality assurance teams, highlighting the need for robust labeling verification processes to maintain consumer trust and market access in the United States.

CLINICAL & PIPELINE
2020-11-02

SUN PHARM INDS LTD Secures FDA Tentative Approval for Generic ANDA210814

SUN PHARM INDS LTD has received Tentative Approval from the FDA for Abbreviated New Drug Application (ANDA) 210814 on November 2, 2020. This signifies the generic drug product meets all regulatory standards but cannot launch due to existing patent or exclusivity protections. This positions Sun Pharma for future market entry, impacting procurement and supply chain strategies for the undisclosed molecule.

CLINICAL & PIPELINE
2020-10-30

INSTAPILL Secures FDA Approval for Generic Loratadine 10mg Orally Disintegrating Tablets

INSTAPILL has received FDA approval for its generic Loratadine 10mg Orally Disintegrating Tablets (ANDA213294) on October 30, 2020. This standard review approval introduces a new over-the-counter option for allergy relief, intensifying competition in the antihistamine market and offering procurement and supply chain leaders an additional sourcing avenue for this widely used molecule.

REGULATORY INTELLIGENCE
2020-10-28

FDA Class III Recall: ANI Pharmaceuticals' Labeling Error on Mixed Amphetamine Salts Impacts Supply

ANI Pharmaceuticals, Inc. initiated a Class III recall (D-0047-2021) for 6,780 bottles of Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended-Release Capsules due to an incorrect 24-month expiration date instead of 18 months. This event highlights critical quality control lapses in labeling for a key CNS stimulant, impacting procurement and regulatory compliance for Amerigen Pharmaceuticals, Inc. and distributors nationwide.

REGULATORY INTELLIGENCE
2020-10-28

FDA Class I Recall: Acella Pharmaceuticals' NP Thyroid 15 Subpotency Raises Critical Supply Chain Concerns

Acella Pharmaceuticals, LLC faced an FDA Class I recall for subpotent NP Thyroid 15 tablets, containing less levothyroxine than labeled. This event, terminated in December 2022, underscores critical quality control and supply chain risks for procurement and regulatory teams in the US pharmaceutical market, demanding enhanced supplier due diligence.

REGULATORY INTELLIGENCE
2020-10-28

FDA Class II Recall: Genesis Partnership Company SA's Subpotent Hand Sanitizer Exposes CGMP Failures

Genesis Partnership Company SA faces an FDA Class II recall for 5,040 bottles of Genesis Hand Sanitizer Gel distributed nationwide in the U.S. The recall, initiated due to CGMP deviations linked to sub-potent ethanol levels, underscores critical quality control failures. This event highlights persistent compliance risks for procurement directors and regulatory affairs heads sourcing OTC products, necessitating enhanced supplier vigilance and robust testing protocols.

REGULATORY INTELLIGENCE
2020-10-21

Leadiant Biosciences CYSTARAN Recall: Subpotent Cysteamine HCl Exposes Ophthalmic Drug Quality Risks

Leadiant Biosciences, Inc. initiated a Class III recall for CYSTARAN (cysteamine ophthalmic solution) due to subpotent Cysteamine HCl. This event, impacting distribution in Pennsylvania and Italy, underscores critical quality control vulnerabilities in contract manufacturing. Procurement and regulatory teams must scrutinize supplier quality agreements and enhance oversight of active pharmaceutical ingredient (API) stability.

CLINICAL & PIPELINE
2020-10-20

SUN PHARM's Discontinued Generic Lansoprazole Receives Multiple Labeling Approvals: Implications for Regulatory Affairs and Supply Chain

SUN PHARM's Abbreviated New Drug Application (ANDA202637) for Lansoprazole 15mg capsules, though discontinued, recently received multiple labeling approvals. This event highlights ongoing regulatory obligations for inactive products and offers no new commercial opportunities. Decision-makers must prioritize compliance for historical portfolios and understand market dynamics for mature generics.

REGULATORY INTELLIGENCE
2020-10-14

FDA Terminates Class II Recall for Calvin Scott & Company's Diethylpropion Due to Repackaging cGMP Failures

Calvin Scott & Company, Inc. faced a Class II FDA recall for Diethylpropion 25 mg tablets, terminated April 22, 2024. The recall stemmed from critical cGMP deviations, specifically repackaging into pouches without supporting stability studies. This event underscores the imperative for robust quality agreements and rigorous oversight of third-party repackaging operations to mitigate supply chain and regulatory risks for procurement and regulatory affairs teams.

REGULATORY INTELLIGENCE
2020-10-07

4e Brands North America Hand Sanitizer Recall: CGMP Failures and Methanol Contamination Risks Highlight Supply Chain Vulnerabilities

4e Brands North America initiated a Class II recall of over 17 million Modesa Hand Sanitizer bottles due to manufacturing in a facility linked to methanol contamination, indicating severe CGMP deviations. This event underscores critical supply chain risks for US importers of OTC drugs, demanding heightened vigilance in supplier qualification and quality oversight to mitigate similar regulatory exposures.

REGULATORY INTELLIGENCE
2020-10-07

Teva Pharmaceuticals' Buprenorphine Transdermal System Recalled by FDA Over Stability Failures

Teva Pharmaceuticals USA initiated a Class II recall for its Buprenorphine Transdermal System 5 mcg/hour due to a critical failure in stability specifications, specifically a below-spec buprenorphine release rate. This nationwide recall, impacting 32,543 cartons manufactured by 3M Drug Delivery Systems, underscores the imperative for robust quality control and supplier oversight in pharmaceutical supply chains to prevent market disruptions and regulatory scrutiny.

REGULATORY INTELLIGENCE
2020-10-07

Arbor Pharmaceuticals' Nymalize Oral Solution Recalled Due to Subpotency: Critical Supply Chain Implications

Arbor Pharmaceuticals initiated a Class III recall of 1,846 cartons of Nymalize (nimodipine) oral solution due to subpotency, impacting nationwide U.S. distribution. This voluntary, firm-initiated action, terminated in February 2022, underscores critical quality control vulnerabilities in neurological drug manufacturing. Procurement and regulatory teams must scrutinize supplier quality systems to mitigate supply chain disruptions and ensure patient safety.

REGULATORY INTELLIGENCE
2020-10-07

ChemLifeIntel Alert: Sun Pharma's RIOMET ER Metformin Recall Highlights Persistent NDMA Contamination Risks

SUN PHARMACEUTICAL INDUSTRIES INC initiated a Class II recall of RIOMET ER (metformin hydrochloride) due to N-nitrosodimethylamine (NDMA) impurity. This terminated recall, impacting 747 bottles, underscores critical cGMP deviations and ongoing nitrosamine risks. Procurement and regulatory teams must enhance supplier scrutiny and diversify sourcing to mitigate supply chain vulnerabilities.

CLINICAL & PIPELINE
2020-10-06

Acella Pharmaceuticals Secures Latest FDA Labeling Approval for Generic Phenytoin Sodium Injectable

Acella Pharmaceuticals, LLC has received FDA approval for a labeling supplement for its generic Phenytoin Sodium injectable (ANDA040573) on October 2, 2024. This update reinforces the product's regulatory compliance and continued market presence, offering stability for procurement and supply chain operations. The 50mg/mL anticonvulsant remains a critical component in epilepsy management, ensuring ongoing access to an established, therapeutically equivalent treatment.

REGULATORY INTELLIGENCE
2020-09-30

FDA Class II Recall of Repackaged Nature-Throid by Preferred Pharmaceuticals, Inc. Highlights CGMP Risks

Preferred Pharmaceuticals, Inc. faced a Class II FDA recall for repackaged Nature-Throid due to CGMP deviations, terminated in April 2024. This event underscores critical supply chain and regulatory risks for procurement, regulatory affairs, and supply chain VPs. Vigilant supplier qualification and continuous monitoring are essential to mitigate disruptions and ensure product quality, particularly with repackaging operations.

REGULATORY INTELLIGENCE
2020-09-30

Perrigo's Albuterol Sulfate Recall: Over 7.7 Million Inhalers Pulled Due to Defective Delivery System

Perrigo Company PLC initiated a Class II recall of 7.7 million Albuterol Sulfate Inhalation Aerosol units due to a defective delivery system. This significant event, involving manufacturer Catalent Pharma Solutions, underscores critical supply chain vulnerabilities for essential respiratory medications. Procurement directors and supply chain VPs must reassess sourcing strategies and quality control for drug-device combination products to mitigate future disruptions.

REGULATORY INTELLIGENCE
2020-09-30

GRUPO YACANA MEXICO Recall: cGMP Deviations Prompted Class II Action on Yacana Alcohol Antiseptic

GRUPO YACANA MEXICO SAS DE CV faced a Class II recall (D-1590-2020) for its Yacana Alcohol Antiseptic 70% Topical Solution due to cGMP deviations. This action, initiated on August 18, 2020, involved 55,560 bottles distributed to Texas. The recall's termination on May 17, 2023, indicates remediation, but highlights persistent quality control risks in cross-border OTC pharmaceutical supply chains for procurement and regulatory teams.

REGULATORY INTELLIGENCE
2020-09-30

AJR Trading LLC Recalls Bio AAA Hand Sanitizer Over Methanol Contamination and CGMP Deviations

AJR TRADING LLC initiated a Class II recall (D-1620-2020) of bio aaa Alcohol en Gel Antibacterial due to manufacturing in a facility where methanol was found in other product lots. This event underscores critical CGMP deviations and supply chain risks for US importers, demanding rigorous supplier qualification and product testing to protect consumer safety and business continuity.

REGULATORY INTELLIGENCE
2020-09-23

Broncolin's HERBACIL Hand Sanitizer Class I Recall: Methanol Contamination Exposes Supply Chain Risks

Broncolin, S.A. de C.V. faced a Class I recall for its HERBACIL Hand Sanitizer due to methanol contamination and subpotent ethanol. This event, impacting 26,972 bottles distributed nationwide in the USA, highlights critical supply chain vulnerabilities and the imperative for rigorous quality control. Procurement and regulatory teams must prioritize supplier vetting and robust testing to mitigate severe public health and commercial risks.

REGULATORY INTELLIGENCE
2020-09-23

FDA Mandates Class I Recall for Maison Terre's Goldenseal Root Powder Organic Due to Microbial Contamination

Maison Terre, LLC faced a Class I FDA recall (D-1584-2020) for its Goldenseal Root Powder Organic due to contamination with dangerous microorganisms, including Enterobacter cloacae. This nationwide event, initiated August 2020, highlights critical quality control failures in non-sterile botanical products. Procurement directors must scrutinize supplier microbial testing and quality systems to mitigate severe public health risks and supply chain disruptions.

REGULATORY INTELLIGENCE
2020-09-23

RLC Labs' Thyroid USP Products Recalled Due to CGMP Deviations: Supply Chain and Regulatory Implications

RLC Labs Inc. initiated a Class II recall (D-1609-2020) for WP Thyroid and Westhroid Pure, 1 Grain (65 mg) Thyroid USP products, citing Current Good Manufacturing Practice (CGMP) deviations that led to subpotent conditions. This event, now terminated, underscores critical quality control vulnerabilities for procurement and regulatory teams managing essential hormone therapies, demanding robust supplier oversight.

REGULATORY INTELLIGENCE
2020-09-23

Real Clean Distribuciones SA de CV Hand Sanitizer Recall: Methanol Contamination Exposes Supply Chain Risks for US Importers

Real Clean Distribuciones SA de CV faced a Class II FDA recall for 917,280 bottles of 'scent theory KEEP CLEAN Moisturizing Hand Sanitizer' due to CGMP deviations, including methanol contamination and sub-potent ethanol. This event highlights critical supply chain vulnerabilities for US firms sourcing personal care products from Mexico, demanding enhanced due diligence and robust quality control protocols to mitigate severe regulatory and reputational risks.

REGULATORY INTELLIGENCE
2020-09-16

FDA Class II Recall: Open Book Extracts' Mislabeled Hand Sanitizer Exposes Critical Methanol Risk

Open Book Extracts initiated a Class II recall of Just Hand Sanitizer (Ethyl Alcohol 73%) due to mislabeling indicating methanol content. This event, impacting 2880 boxes distributed nationwide, underscores critical supply chain and regulatory risks. Decision-makers must enhance supplier vetting and labeling controls to mitigate similar hazards and safeguard consumer trust.

REGULATORY INTELLIGENCE
2020-09-16

Teva Pharmaceuticals Recalls 1.46 Million Cephalexin Bottles Over CGMP Deviations

Teva Pharmaceuticals USA, Inc. initiated a Class II voluntary recall (D-0013-2021) for 1,467,535 bottles of Cephalexin for Oral Suspension due to Current Good Manufacturing Practice (CGMP) deviations. This event, now terminated, highlights critical quality control risks where active ingredient levels were potentially outside specification limits. Procurement and regulatory teams must scrutinize supplier quality systems, even for generic products, to mitigate supply chain disruptions and ensure patient safety.

REGULATORY INTELLIGENCE
2020-09-09

FDA Class I Recall: SG24 LLC's SkinGuard 24 Hand Sanitizer Deemed Unapproved Drug Due to Methanol Content

SG24 LLC faced a Class I FDA recall for its SkinGuard 24 All-Day Hand Sanitizer, distributed nationwide from Bolingbroke, GA. The product, containing 0.56% methanol, was deemed an unapproved new drug, lacking required NDA/ANDA clearance. This event underscores critical regulatory compliance risks for chemical and life sciences firms, highlighting the imperative for rigorous ingredient verification and market authorization before product launch to avoid significant market disruptions and reputational damage.

REGULATORY INTELLIGENCE
2020-09-09

AAA Cosmetica Faces Severe Regulatory Scrutiny Following Class I Methanol Contamination Recall

AAA Cosmetica, SA de CV initiated a Class I recall of over 200,000 bottles of bio aaa Advance Hand Sanitizer due to methanol contamination. This severe regulatory event highlights critical quality control failures, posing significant health risks. Procurement and regulatory teams must reassess supplier vetting, especially for imported products, to mitigate similar supply chain vulnerabilities and ensure consumer safety.

REGULATORY INTELLIGENCE
2020-09-09

Laboratorios Jaloma Recalls 211,875 Hand Sanitizer Bottles Over cGMP Deviations: Supply Chain Implications

Laboratorios Jaloma S.A. de C.V. initiated a Class II recall of 211,875 bottles of Jaloma Antiseptic Hand Sanitizer due to cGMP deviations at its Guadalajara, Mexico facility. This event, terminated in August 2022, underscores persistent quality control challenges for OTC drug manufacturers. Procurement and regulatory teams must scrutinize supplier cGMP compliance, especially for critical products like sanitizers, to mitigate supply chain disruptions and ensure product integrity for end-users.

REGULATORY INTELLIGENCE
2020-09-09

FDA Class II Recall: Santa Cruz Biotechnology's Subpotent Hand Sanitizer Exposes Potency Control Gaps

Santa Cruz Biotechnology, Inc. faced a Class II FDA recall for 14,238 bottles of UltraCruz Hand Sanitizing Gel due to subpotency. This event, initiated August 7, 2020, and terminated June 14, 2021, highlights critical quality control vulnerabilities in pharmaceutical manufacturing. Procurement and regulatory teams must scrutinize supplier quality agreements and implement robust testing protocols to mitigate similar supply chain risks.

REGULATORY INTELLIGENCE
2020-09-02

Fresenius Kabi's Class I Dexmedetomidine HCl Recall Signals Critical Cross-Contamination Risks

Fresenius Kabi USA, LLC initiated a Class I recall of 25,100 bottles of Dexmedetomidine HCl due to trace lidocaine cross-contamination. This event, terminated in September 2022, underscores severe quality control vulnerabilities in sterile injectable manufacturing. Procurement and regulatory teams must scrutinize supplier quality systems to mitigate supply chain disruption and patient safety risks from such critical drug product issues.

REGULATORY INTELLIGENCE
2020-09-02

FDA Class II Recall: Par Pharmaceutical's BusPIRone Hydrochloride Tablets Fail Impurity Specifications

Par Pharmaceutical Inc. initiated a Class II recall of 11,347 bottles of BusPIRone Hydrochloride Tablets, USP 7.5 mg, due to failed impurity specifications. This voluntary action, terminated in June 2021, underscores the critical need for robust quality control in pharmaceutical manufacturing. Procurement and regulatory teams must assess supplier quality systems to mitigate supply chain disruptions and compliance risks.

REGULATORY INTELLIGENCE
2020-09-02

BAYSHORE PHARMACEUTICALS' Metformin Hydrochloride Recall Highlights Persistent CGMP Risks in Global Supply Chains

BAYSHORE PHARMACEUTICALS initiated a nationwide Class II recall of Metformin Hydrochloride Extended-Release Tablets due to CGMP deviations. This event, involving product manufactured by Beximco Pharmaceuticals, LTD. in Bangladesh, underscores critical quality control challenges within global pharmaceutical supply chains. Procurement and regulatory teams must enhance supplier diligence to mitigate similar disruptions and ensure patient safety.

REGULATORY INTELLIGENCE
2020-09-02

FDA Class I Recall: SCA Pharmaceuticals' Heparin Sodium Contained Undeclared Benzyl Alcohol, Highlighting Critical Quality Control Gaps

SCA Pharmaceuticals initiated a Class I recall for 362 containers of Heparin Sodium 10,000 units/mL due to undeclared benzyl alcohol, mislabeled as parabens. This event, terminated in May 2021, underscores critical quality control and labeling deficiencies, posing significant risks for procurement and regulatory teams managing pharmaceutical supply chain integrity and patient safety.

REGULATORY INTELLIGENCE
2020-09-02

FDA Class II Recall: Resource Recovery & Trading LLC's Hand Sanitizer Pulled Due to cGMP Deviations

RESOURCE RECOVERY & TRADING LLC initiated a Class II recall for 115 bottles of HAND SANITIZER Non-sterile Solution 70% Topical Solution due to cGMP deviations. This event, impacting distribution in AL and GA, underscores critical supply chain and regulatory risks for procurement directors and regulatory affairs heads sourcing drug products, even from distributors.

REGULATORY INTELLIGENCE
2020-08-26

Ultra Seal Corporation's Pain Relief Recall Highlights Critical Aspirin Stability Failures and Supply Chain Risks

Ultra Seal Corporation initiated a Class III recall for 4.6 million packets of Pain Relief Maximum Strength tablets due to out-of-specification Salicylic Acid levels, a critical aspirin degradation product. This event underscores persistent quality control challenges in OTC drug manufacturing, demanding enhanced due diligence from procurement and regulatory teams managing complex supply chains and contract manufacturing relationships.

CLINICAL & PIPELINE
2020-08-26

FDA Approves CARBAGLU Labeling Update for Recordati Rare Diseases' Orphan Drug

Recordati Rare Diseases secured FDA approval for a supplemental labeling update for its orphan drug, CARBAGLU (carglumic acid), on January 19, 2024. This standard review approval, following earlier efficacy expansions, signals refined prescribing information. For procurement, regulatory, and supply chain leaders, this reinforces CARBAGLU's market position, necessitating vigilance on updated compliance protocols and patient access strategies for this critical rare disease therapy.

REGULATORY INTELLIGENCE
2020-08-26

Calvin Scott & Company's Phentermine Recall Highlights Critical CGMP Packaging Failures

Calvin Scott & Company, Inc. initiated a Class II recall for Phentermine 15mg capsules due to critical CGMP deviations. Light-sensitive drug products were repackaged into transparent pouches, compromising product integrity. This event, now terminated, underscores the necessity for robust packaging controls in pharmaceutical supply chains, impacting procurement and regulatory compliance for distributors in the United States.

REGULATORY INTELLIGENCE
2020-08-26

Ferring Pharmaceuticals Faces Class I Recall for Superpotent Desmopressin Acetate Nasal Spray

Ferring Pharmaceuticals Inc. initiated a Class I recall of 184,325 units of Desmopressin Acetate Nasal Spray due to superpotency. This event, terminated after three years, underscores critical quality control failures and significant patient safety risks. Procurement and regulatory teams must scrutinize supplier agreements and ensure robust quality management systems to mitigate similar supply chain vulnerabilities.

REGULATORY INTELLIGENCE
2020-08-26

CareFusion 213, LLC Initiates Class I Recall of ChloraPrep Applicators Due to Aspergillus Penicilloides Contamination

CareFusion 213, LLC, a Becton, Dickinson and Company subsidiary, executed a Class I recall of 2.8 million ChloraPrep applicators due to *Aspergillus Penicilloides* contamination. This global event, impacting 16 countries, underscores critical non-sterility risks in pre-operative skin preparations. Procurement and regulatory teams must scrutinize supplier quality systems to mitigate similar supply chain disruptions.

REGULATORY INTELLIGENCE
2020-08-19

FDA Class II Recall: PAI Holdings' Subpotent Nystatin Oral Suspension Exposes Quality Control Gaps

PAI Holdings, LLC. dba Pharmaceutical Associates Inc initiated a Class II recall for subpotent Nystatin Oral Suspension. This event highlights critical quality control vulnerabilities, impacting procurement strategies and regulatory compliance for pharmaceutical buyers. Decision-makers must reassess supplier stability and diversify sourcing to mitigate future supply chain disruptions.

REGULATORY INTELLIGENCE
2020-08-19

Eosera, Inc. Faces FDA Class II Recall for Ear Itch MD Due to cGMP Deviations

Eosera, Inc. initiated a Class II recall for 43,424 bottles of Ear Itch MD Anti-Itch Spray (pramoxine HCL 1%) across the U.S. due to cGMP deviations. This event, terminated by the FDA in September 2021, underscores critical quality control vulnerabilities. Procurement and regulatory teams must scrutinize supplier compliance, especially for OTC drug products, to mitigate supply chain and reputational risks.

REGULATORY INTELLIGENCE
2020-08-19

Itech 361 LLC Hand Sanitizer Recall: Undeclared Methanol Exposes Critical Supply Chain Gaps

Itech 361 LLC initiated a Class I recall of 18,760 bottles of All Clean Hand Sanitizer due to undeclared methanol. This event, involving Mexican producer Eskbiochem SA de CV, highlights severe supply chain vulnerabilities and the critical need for enhanced due diligence for procurement directors and regulatory affairs heads to mitigate significant commercial and safety risks.

REGULATORY INTELLIGENCE
2020-08-19

Taro Pharmaceuticals Recalls Clobetasol Propionate Cream Over Content Uniformity Failure

Taro Pharmaceuticals U.S.A., Inc. recalled Clobetasol Propionate Cream USP, 0.05% due to content uniformity failure in the bulk lot. This Class III recall, initiated July 20, 2020, and terminated June 20, 2023, highlights critical quality control lapses at the Canadian manufacturing facility. Decision-makers must scrutinize supplier quality systems for topical formulations, ensuring robust blending and in-process controls to mitigate supply chain risks and safeguard patient safety.

CLINICAL & PIPELINE
2020-08-19

TERSERA's VARUBI (ROLAPITANT HYDROCHLORIDE) IV Emulsion: FDA Approval and Subsequent Discontinuation Impact

TERSERA's VARUBI (ROLAPITANT HYDROCHLORIDE) intravenous emulsion received FDA approval as a new dosage form (NDA208399) on October 25, 2017. Despite initial regulatory success, the product's marketing status is now discontinued. This event signals critical considerations for regulatory affairs, procurement, and business development teams regarding product lifecycle management and market dynamics for antiemetic therapies.

CLINICAL & PIPELINE
2020-08-18

FDA Approves APIL's ATELVIA (Risedronate Sodium) as New Delayed-Release Dosage Form

The FDA approved APIL's NDA022560 for ATELVIA (Risedronate Sodium) as a Type 3 new delayed-release dosage form on October 8, 2010. This strategic approval for the 35MG oral tablet differentiates APIL's product in the market, necessitating ongoing regulatory and supply chain vigilance for this long-lifecycle asset, with updates extending to 2026.

REGULATORY INTELLIGENCE
2020-08-12

MICHIGAN HERBAL REMEDIES CBD Oil Recalled Nationwide Due to Class I Lead Contamination

MICHIGAN HERBAL REMEDIES initiated a Class I recall of its BC Hemp Co. Full Spectrum Hemp Extract CBD Oil due to elevated, undeclared lead levels. This nationwide distribution event, D-1457-2020, underscores critical supply chain vulnerabilities in botanical extracts. Procurement, regulatory, and supply chain leaders must implement stringent heavy metal testing and robust supplier qualification to mitigate severe health risks and protect brand integrity in the evolving CBD market.

REGULATORY INTELLIGENCE
2020-08-12

Summitt Labs' KORE ORGANIC CBD Oil Recalled Nationwide Due to Class I Lead Contamination

Summitt Labs initiated a Class I recall of 236 bottles of KORE ORGANIC CBD Oil Watermelon 15mg nationwide due to elevated lead levels. This event underscores critical chemical contamination risks in nutraceutical supply chains, demanding heightened vigilance from procurement and regulatory teams. The recall, D-1489-2020, highlights the imperative for robust quality control.

REGULATORY INTELLIGENCE
2020-08-12

Vilvet Pharmaceuticals' VILEVEV MB Recall Highlights Persistent cGMP Compliance Risks for Urinary Antiseptics

Vilvet Pharmaceuticals Inc. initiated a Class II nationwide recall of 1,716 bottles of VILEVEV MB Urinary Antispetic due to cGMP deviations. This event, terminated in January 2022, underscores persistent quality control challenges in pharmaceutical manufacturing. Procurement and regulatory teams must enhance supplier due diligence and quality oversight to mitigate supply chain disruptions and ensure patient safety from similar compliance risks.

REGULATORY INTELLIGENCE
2020-08-05

MasterPharm LLC's Formula 82M Recall Highlights Critical Processing Control Lapses

MasterPharm LLC faced a Class II recall for 543 units of Formula 82M due to a lack of processing controls, impacting nationwide U.S. distribution. This event underscores the critical need for robust quality assurance in pharmaceutical manufacturing, prompting procurement and regulatory teams to re-evaluate supplier vetting and compliance oversight to mitigate supply chain risks.

REGULATORY INTELLIGENCE
2020-08-05

Sun Pharma's Clonazepam Recall Signals Persistent Cross-Contamination Risks in US Pharmaceutical Supply Chains

Sun Pharmaceutical Industries Inc. initiated a Class III recall of Clonazepam Orally Disintegrating Tablets due to clozapine cross-contamination, impacting 3,516 bottles nationwide. This event, now terminated, highlights critical manufacturing control vulnerabilities. Procurement and regulatory teams must scrutinize supplier quality systems to mitigate similar risks and ensure patient safety and supply chain integrity.

REGULATORY INTELLIGENCE
2020-08-05

UVT INC's Saniderm Hand Sanitizer Recall: Undeclared Methanol Exposes Critical Supply Chain Vulnerabilities

UVT INC initiated a Class I recall of 38,016 bottles of Saniderm ADVANCED HAND SANITIZER due to undeclared methanol, produced by Eskbiochem SA de CV. This event underscores severe risks in global supply chains for OTC products, demanding enhanced due diligence and robust quality control from procurement and regulatory teams to mitigate health hazards and commercial liabilities.

CLINICAL & PIPELINE
2020-08-05

Strides Pharma Intl Secures FDA Approval for Generic Sevelamer Carbonate 800mg Tablets

Strides Pharma Intl secured FDA approval for its Abbreviated New Drug Application (ANDA201069) for Sevelamer Carbonate 800mg tablets on August 5, 2020. This approval positions Strides Pharma Intl to enter the market for this critical molecule, particularly significant given the reference product's discontinued status. Procurement and supply chain leaders should evaluate Strides Pharma Intl as a new, viable source, enhancing supply diversification and cost management strategies.

REGULATORY INTELLIGENCE
2020-08-05

Allergan PLC Initiates Nationwide Recall of Skin Medica Acne System Due to Subpotency

Allergan PLC voluntarily recalled 8,555 Skin Medica Acne System kits nationwide due to subpotent Salicylic Acid and Benzoyl Peroxide. This Class III recall, initiated July 6, 2020, and terminated February 28, 2024, highlights critical quality control failures. Procurement directors must assess supplier stability data, while regulatory affairs and supply chain VPs should review internal quality assurance protocols to mitigate similar risks.

REGULATORY INTELLIGENCE
2020-08-05

FDA Terminates Recall of WORLD EVENT PROMOTIONS' Subpotent Handese Hand Sanitizer: Key Lessons for OTC Quality Control

The FDA has terminated the Class II recall of WORLD EVENT PROMOTIONS, LLC's Handese Advanced Instant Hand Sanitizer. This action, initiated due to subpotency of Ethyl Alcohol 70% and high pH levels, highlights critical quality control failures in OTC drug manufacturing. Procurement and regulatory teams must reinforce supplier qualification and robust analytical testing protocols to mitigate similar supply chain risks.

CLINICAL & PIPELINE
2020-07-31

Amneal Pharmaceuticals' Tigecycline NDA: Supply Chain Diversification Amidst Compliance Scrutiny

Amneal Pharmaceuticals secured FDA approval for TIGECYCLINE (NDA211158) as a new manufacturer in August 2018, diversifying the supply of this critical intravenous antibacterial. While a recent labeling update in March 2025 confirms ongoing regulatory compliance, procurement and supply chain leaders must critically assess Amneal's documented history of high-severity CGMP risks and Metformin recalls, necessitating enhanced due diligence for TIGECYCLINE sourcing to mitigate potential supply disruptions.

REGULATORY INTELLIGENCE
2020-07-29

Lupin Pharmaceuticals' Cefdinir Recall Highlights Critical Superpotency Risks and Supply Chain Vulnerabilities

Lupin Pharmaceuticals Inc. initiated a Class II recall of Cefdinir for Oral Suspension due to superpotency, stemming from out-of-specification assay results. This event, impacting 35,928 bottles nationwide, underscores persistent quality control challenges within the global pharmaceutical supply chain. Procurement and regulatory teams must scrutinize Lupin's manufacturing oversight and diversify sourcing strategies to mitigate future disruptions and ensure product integrity.

REGULATORY INTELLIGENCE
2020-07-29

FDA Class III Recall of Fresenius Kabi's Famotidine Injection Highlights Critical Cold Chain Gaps

Fresenius Kabi USA, LLC's Famotidine Injection faced a Class III FDA recall due to temperature abuse during distribution, impacting a single lot. This event underscores the critical need for robust cold chain management and rigorous oversight of logistics partners. Procurement and supply chain leaders must enhance audit protocols to safeguard product integrity and patient safety.

REGULATORY INTELLIGENCE
2020-07-22

Granules Pharmaceuticals' Metformin ER Recall: NDMA Contamination Exposes Global Supply Chain Risks

Granules Pharmaceuticals Inc. initiated a nationwide Class II recall (D-1386-2020) for Metformin Hydrochloride Extended-Release Tablets, 750 mg, due to N-Nitrosodimethylamine (NDMA) impurity levels exceeding acceptable limits. This voluntary action, stemming from FDA analysis detecting CGMP deviations, impacts 476,073 bottles of 100-count and 2,100 bottles of 500-count, manufactured by Granules India Limited. This event underscores persistent quality control challenges in the global Metformin supply chain.

REGULATORY INTELLIGENCE
2020-07-22

Akorn's Proparacaine Hydrochloride Recall: Critical Lessons from Chemical Contamination and Cleaning Failures

Akorn, Inc. faced a Class III recall for Proparacaine Hydrochloride Ophthalmic Solution due to chemical contamination from out-of-specification equipment cleaning. This event, originating from their Lake Forest, IL facility, underscores critical vulnerabilities in sterile manufacturing quality control. Decision-makers must scrutinize supplier cleaning validation and ensure robust supply chain resilience for ophthalmic products.

REGULATORY INTELLIGENCE
2020-07-22

Fresenius Kabi Fosaprepitant Recall: Excipient Labeling Error Impacts US Supply Chain

Fresenius Kabi USA, LLC initiated a Class III recall for 63,067 vials of Fosaprepitant for Injection due to an excipient labeling error. The carton incorrectly stated edetate disodium quantity, highlighting critical regulatory compliance and supply chain oversight needs. This event underscores the imperative for robust quality control and accurate product information for pharmaceutical procurement and regulatory teams.

REGULATORY INTELLIGENCE
2020-07-22

Lupin Pharmaceuticals Metformin Recall: NDMA Contamination Exposes CGMP Risks

Lupin Pharmaceuticals initiated a Class II recall for Metformin Hydrochloride Extended-release Tablets due to N-Nitrosodimethylamine (NDMA) impurity exceeding acceptable levels. This voluntary action, stemming from CGMP deviations at its Goa, India, facility, highlights critical supply chain vulnerabilities for procurement and regulatory teams managing generic drug portfolios in the United States.

REGULATORY INTELLIGENCE
2020-07-15

Biogen's Tecfidera Recall: Critical cGMP Deviations Impact US Pharmaceutical Supply Chain

Biogen Inc. initiated a Class III recall of 3,922 bottles of Tecfidera (dimethyl fumarate) due to cGMP deviations, specifically distributing a lot rejected during in-process control. This event, now terminated, highlights critical quality control vulnerabilities for pharmaceutical procurement and supply chain leaders, emphasizing the imperative for stringent supplier oversight and robust internal quality assurance protocols.

REGULATORY INTELLIGENCE
2020-07-15

Somerset Therapeutics' Brimonidine Tartrate Recall Highlights Ophthalmic Product Stability Risks

Somerset Therapeutics, LLC initiated a Class III recall of 48,852 bottles of Brimonidine Tartrate Ophthalmic Solution 0.2% due to label leaching impacting product stability. This event, now terminated, underscores critical packaging material compatibility challenges and the imperative for robust quality control in global pharmaceutical supply chains, particularly for generic ophthalmic drugs manufactured in India for the US market.

REGULATORY INTELLIGENCE
2020-07-08

FDA Class II Recall: The Harvard Drug Group's Metformin Hydrochloride Impurity Highlights Persistent NDMA Risks

The Harvard Drug Group initiated a Class II recall (D-1360-2020) for Metformin Hydrochloride Extended-Release Tablets, 500 mg, due to potential Nitrosodimethylamine (NDMA) impurity exceeding established levels. This event, impacting 1,906 cartons distributed nationwide, underscores persistent CGMP risks in the pharmaceutical supply chain. Decision-makers must reinforce supplier qualification and enhance analytical testing protocols for active pharmaceutical ingredients.

REGULATORY INTELLIGENCE
2020-07-08

Beaming White Llc's Koala Hand Sanitizer Recall: Subpotent Ethanol and Undeclared Isopropyl Alcohol Expose Supply Chain Risks

Beaming White Llc initiated a Class II recall for its Koala Hand Sanitizer due to subpotent ethyl alcohol and undeclared isopropyl alcohol. This event, terminated in March 2024, highlights critical quality control failures and ingredient transparency issues in OTC drug manufacturing. Procurement and regulatory teams must enhance supplier vigilance to mitigate similar supply chain vulnerabilities and ensure product efficacy.

CLINICAL & PIPELINE
2020-07-02

Teva Pharmaceuticals Secures Tentative FDA Approval for Generic Apixaban (ANDA210142)

Teva Pharmaceuticals USA Inc. has received Tentative Approval from the FDA for its generic APIXABAN 2.5mg oral tablets (ANDA210142) on August 21, 2020. This confirms bioequivalence and manufacturing readiness, positioning Teva for market entry once patent and exclusivity barriers expire. Decision-makers should prepare for future supply chain diversification and increased market competition in the anticoagulant sector, leveraging this regulatory milestone for strategic planning.

REGULATORY INTELLIGENCE
2020-07-01

Teva's Metformin Recall Highlights Persistent NDMA Contamination and CGMP Risks

Teva Pharmaceuticals USA initiated a Class II recall of Metformin Hydrochloride Extended-Release Tablets due to N-Nitrosodimethylamine (NDMA) impurity above acceptable levels, stemming from CGMP deviations. This event, now terminated, underscores critical supply chain and regulatory risks for procurement and quality assurance teams, demanding rigorous oversight of contract manufacturers like Watson Pharma Private Limited.

REGULATORY INTELLIGENCE
2020-07-01

Aurobindo Pharma's Clozapine Recall: Foreign Tablet Contamination Exposes Critical Supply Chain Vulnerabilities

Aurobindo Pharma USA Inc. initiated a Class II recall for 1,440 bottles of Clozapine Tablets USP 100mg due to foreign tablet contamination. This event, now terminated, highlights critical quality control vulnerabilities in pharmaceutical manufacturing and distribution. Procurement and regulatory teams must scrutinize supplier quality systems, particularly for generic antipsychotics like Clozapine, to safeguard patient safety and ensure supply chain integrity against similar deviations.

REGULATORY INTELLIGENCE
2020-07-01

FDA Class III Recall: Rising Pharmaceuticals' Timolol Maleate Ophthalmic Solution Labeling Error Exposes Supply Chain Vulnerabilities

Rising Pharmaceuticals, Inc. initiated a Class III recall for Timolol Maleate Ophthalmic Solution due to a critical labeling mix-up. A 0.25% strength bottle was incorrectly packaged in a 0.5% strength carton. This event, now terminated, underscores the imperative for robust quality control in pharmaceutical supply chains, particularly for products manufactured by FDC Limited in India and distributed nationwide across the U.S.

REGULATORY INTELLIGENCE
2020-07-01

Crown Laboratories' Nystatin Cream Recall: Subpotency Exposes Stability Testing Gaps in Topical Antifungal Supply

Crown Laboratories initiated a Class II recall for 62,274 tubes of Nystatin Cream due to subpotency, impacting nationwide distribution. This event underscores critical vulnerabilities in stability testing and quality control for topical antifungal products, demanding immediate review of supplier qualification and internal quality assurance protocols by procurement and regulatory teams.

REGULATORY INTELLIGENCE
2020-07-01

FDA Class II Recall: BIOTA Biosciences' Sterile CBD + Curcumin Vials Flagged for Sterility and Unapproved Drug Status

BIOTA Biosciences LLC initiated a Class II recall for its Sterile Cannabidiol (CBD) + Curcumin 50mg/mL vials due to sterility assurance failures and marketing an unapproved drug. This event, impacting US and New Zealand markets, underscores critical regulatory and quality control risks for procurement and regulatory teams. Companies must scrutinize suppliers of novel compounds like CBD for robust FDA compliance and manufacturing integrity to mitigate supply chain disruptions.

REGULATORY INTELLIGENCE
2020-07-01

Amneal Pharmaceuticals Metformin Recall: NDMA Contamination Exposes Persistent CGMP Risks

Amneal Pharmaceuticals of New York, LLC initiated a nationwide Class II recall of Metformin Hydrochloride Extended-Release Tablets due to N-Nitrosodimethylamine (NDMA) impurity exceeding acceptable levels. This event underscores persistent CGMP deviations and systemic nitrosamine contamination risks across the pharmaceutical supply chain, demanding immediate attention from procurement and regulatory leaders to ensure product safety and supply continuity.

REGULATORY INTELLIGENCE
2020-07-01

Lupin Pharmaceuticals' Metformin Recall: NDMA Contamination Exposes CGMP Deviations and Supply Chain Risks

Lupin Pharmaceuticals Inc. executed a Class II recall of Metformin Hydrochloride Extended-release Tablets due to N-Nitrosodimethylamine (NDMA) impurity exceeding acceptable limits, stemming from CGMP deviations at its Goa, India manufacturing site. This event underscores critical quality control vulnerabilities within global pharmaceutical supply chains, necessitating immediate action from procurement and regulatory affairs to mitigate patient safety risks and ensure supply continuity for this essential diabetes medication.

REGULATORY INTELLIGENCE
2020-07-01

Amneal Pharmaceuticals Recalls Metformin Due to NDMA Contamination, Highlighting Systemic CGMP Risks

Amneal Pharmaceuticals of New York, LLC initiated a Class II recall (D-1348-2020) for Metformin Hydrochloride Extended-Release Tablets, 750 mg, due to N-Nitrosodimethylamine (NDMA) impurity exceeding acceptable levels, identified by FDA analysis. This event underscores persistent Current Good Manufacturing Practice (CGMP) deviations within the pharmaceutical supply chain, demanding immediate attention from procurement and regulatory leaders.

REGULATORY INTELLIGENCE
2020-06-24

Aurobindo Pharma USA Recalls Olanzapine Tablets Over Impurity and Degradation Failures

Aurobindo Pharma USA Inc. initiated a Class III nationwide recall (D-1315-2020) for 7,547 bottles of Olanzapine Tablets, USP 7.5 mg, manufactured by Aurolife Pharma LLC. The action, terminated January 10, 2023, stemmed from failed impurities/degradation specifications. This highlights critical quality control vulnerabilities for procurement and regulatory teams, necessitating rigorous supplier oversight, especially for generic pharmaceuticals distributed through partners like Prasco Laboratories.

REGULATORY INTELLIGENCE
2020-06-24

FDA Class II Recall: SCA Pharmaceuticals' Heparin Sodium Subpotency Exposes Critical Quality Control Failures

SCA Pharmaceuticals initiated a Class II recall of Heparin Sodium 5,000 units/mL due to subpotency, impacting hospitals in PA and CA. This event, coupled with a prior Class I recall for Heparin Sodium, signals persistent quality control deficiencies. Procurement and regulatory teams must scrutinize SCA's manufacturing processes and ensure robust supplier qualification to mitigate supply chain risks.

REGULATORY INTELLIGENCE
2020-06-24

Haleon US Holdings LLC Faces FDA Scrutiny Over Gaviscon Labeling Non-Compliance, Prompting Nationwide Recall

Haleon US Holdings LLC initiated a nationwide Class II recall (D-1323-2020) for 151,344 bottles of Gaviscon Regular Strength Liquid Antacid Cool Mint due to missing Magnesium safety warnings. This FDA-classified regulatory compliance breach underscores critical risks for procurement and regulatory teams in OTC drug labeling, demanding enhanced vigilance in quality control and supply chain oversight to prevent market disruption and reputational damage.

REGULATORY INTELLIGENCE
2020-06-17

Fresenius Kabi USA Recalls 5.3 Million Vials of Ketorolac Tromethamine Due to Particulate Matter

Fresenius Kabi USA, LLC initiated a Class I recall for 5,314,400 vials of Ketorolac Tromethamine Injection, USP, 30 mg per mL, due to particulate matter. This significant event, active from April 2020 to October 2023, posed substantial supply chain risks and patient safety concerns across the USA and Puerto Rico, demanding immediate action from procurement and regulatory teams to ensure continuity of critical injectable pain management therapies.

REGULATORY INTELLIGENCE
2020-06-17

Unichem Pharmaceuticals USA Inc. Initiates Nationwide Recall of Clonidine Hydrochloride Tablets Due to Benzophenone Contamination

Unichem Pharmaceuticals USA Inc. has completed a Class III recall of 190,992 bottles of Clonidine Hydrochloride Tablets nationwide. The recall, initiated voluntarily, addressed potential benzophenone migration from product containers, failing impurity specifications. This event underscores critical risks in pharmaceutical packaging integrity and the necessity for rigorous supplier and material qualification processes for procurement and regulatory teams.

REGULATORY INTELLIGENCE
2020-06-10

Teva Pharmaceuticals Recalls Mixed Amphetamine Salts Tablets Over Mixed Strengths

Teva Pharmaceuticals USA, Inc. initiated a Class II recall for 33,280 bottles of its Mixed Amphetamine Salts Tablets due to mixed strengths within bottles. This voluntary action, terminated in May 2021, highlights critical quality control vulnerabilities impacting product efficacy and patient safety. Procurement and regulatory teams must scrutinize supplier quality systems for similar high-risk products.

REGULATORY INTELLIGENCE
2020-06-10

AvKARE Lamotrigine Recall: Foreign Substance Contamination Exposes Supply Chain Vulnerabilities

AvKARE's Class III recall of Lamotrigine Tablets, USP, 150 mg, due to desiccant granule contamination, highlights critical quality control lapses. This event, coupled with AvKARE's prior recalls, signals heightened supply chain risks. Procurement and regulatory teams must intensify due diligence for products sourced from or distributed by AvKARE to mitigate potential disruptions.

REGULATORY INTELLIGENCE
2020-06-10

TRIOVA PHARMACEUTICALS LLC Estriol Recall: Organic Impurity Failures Expose API Quality Control Gaps

TRIOVA PHARMACEUTICALS LLC initiated a Class II nationwide recall of Estriol USP Micronized 5 G due to failed organic impurities and degradation specifications. This event, now terminated, highlights critical quality control vulnerabilities in API supply chains. Procurement and regulatory teams must reinforce supplier qualification and analytical testing protocols to mitigate risks from out-of-specification raw materials, safeguarding product integrity and patient safety.

REGULATORY INTELLIGENCE
2020-06-10

Acella Pharmaceuticals' NP Thyroid 60 Class I Recall: Superpotency Risks and Supply Chain Implications

Acella Pharmaceuticals, LLC initiated a Class I recall of 29,304 bottles of NP Thyroid 60 (Levothyroxine, Liothyronine) due to superpotency, posing significant patient risk and supply chain disruption. This event, terminated in January 2022, underscores critical quality control vulnerabilities for manufacturers of thyroid hormone replacement therapies, demanding rigorous supplier vetting and robust analytical testing protocols from procurement and regulatory teams.

REGULATORY INTELLIGENCE
2020-06-10

Teva Pharmaceuticals USA Recalls Mixed Amphetamine Salts Tablets Over Strength Discrepancies

Teva Pharmaceuticals USA initiated a Class II recall of 41,348 bottles of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets due to mixed strengths. This voluntary action, terminated in May 2021, highlights critical quality control vulnerabilities, impacting patient safety and supply chain stability for this essential ADHD medication across the US and Puerto Rico.

REGULATORY INTELLIGENCE
2020-06-03

West-Ward Columbus Inc Initiates Class II Recall of Doxycycline Hyclate Tablets Due to Dissolution Failure

West-Ward Columbus Inc initiated a Class II recall (D-1274-2020) for 68,376 bottles of Doxycycline Hyclate Tablets due to failed dissolution specifications at shelf-life end. This event, now terminated, highlights critical quality control vulnerabilities for generic antibiotic suppliers. Procurement and supply chain leaders must scrutinize quality assurance protocols and diversify sourcing for essential medicines like Doxycycline Hyclate to mitigate disruption risks and ensure patient access.

REGULATORY INTELLIGENCE
2020-06-03

FDA Recall: Wuhan Bingbing Pharmaceutical's CGMP Failures Impact US Mencaine Patch Supply

Wuhan Bingbing Pharmaceutical Co., Ltd. initiated a Class II recall of Mencaine Patches due to critical CGMP deviations, specifically lost manufacturing records and retain samples. This impacts 1,800 pouches distributed nationwide in the USA, manufactured for Terrain Pharmaceuticals. This event underscores persistent global supply chain vulnerabilities and demands heightened due diligence from procurement and regulatory teams.

CLINICAL & PIPELINE
2020-05-28

Rubicon Research's Generic Buspirone Hydrochloride Approval: A Deep Dive into Early Market Entry and Supply Chain Dynamics

Rubicon Research secured FDA approval for its Abbreviated New Drug Application (ANDA075521) for generic BUSPIRONE HYDROCHLORIDE tablets on April 5, 2002. This early market entry for the anxiolytic drug provided significant commercial advantage. The approval, covering multiple strengths, highlights strategic generic positioning and ongoing regulatory compliance, with Advagen Pharma Ltd. identified as a key manufacturing partner in the supply chain.

REGULATORY INTELLIGENCE
2020-05-27

InvaGen Pharmaceuticals' Gabapentin Recall: Impurity Failure Exposes Generic Drug Stability Risks

InvaGen Pharmaceuticals initiated a Class III recall of Gabapentin Tablets USP, 600 mg, due to Impurity A failure during stability testing. This event, affecting 2,202 bottles distributed nationwide, underscores critical quality control vulnerabilities in generic drug manufacturing. Procurement directors must reassess supplier stability protocols, while regulatory affairs must ensure robust impurity monitoring to safeguard product integrity and patient safety.

REGULATORY INTELLIGENCE
2020-05-27

ICU Medical Inc. Recalls 93,648 Units of Lactated Ringer's Injection Due to Iron Oxide Particulate Matter

ICU Medical Inc. initiated a Class I recall for 93,648 units of LACTATED RINGER'S Injection, USP 1000 mL, manufactured by Hospira, Inc., due to confirmed iron oxide particulate matter. This event, now terminated, underscores critical supply chain vulnerabilities for essential injectables. Procurement and regulatory teams must scrutinize quality agreements and diversify sourcing to mitigate patient safety risks and ensure continuity of care amidst persistent industry-wide quality control challenges.

REGULATORY INTELLIGENCE
2020-05-27

West-Ward Columbus Inc's Ethacrynic Acid Recall Signals Persistent Impurity Control Challenges for US Supply

West-Ward Columbus Inc initiated a Class III recall of Ethacrynic Acid Tablets due to out-of-specification impurities and degradants. This event, impacting 3,336 bottles distributed nationwide, highlights critical quality control vulnerabilities. For procurement and regulatory teams, it signals potential systemic issues, reinforcing the need for stringent supplier oversight and robust risk mitigation strategies given the company's prior compliance history.

REGULATORY INTELLIGENCE
2020-05-20

Haleon US Holdings LLC Initiates Class III Recall for ChapStick Total Hydration Due to Packaging Separation

Haleon US Holdings LLC, formerly Glaxosmithkline Consumer Healthcare Holdings, initiated a Class III recall (D-1267-2020) for ChapStick Total Hydration Moisture + Tint + SPF15 Very Berry due to secondary packaging separation. This voluntary action, affecting 288 packages nationwide, highlights the critical need for robust quality control in packaging processes, impacting supply chain integrity and brand perception for OTC drug products.

CLINICAL & PIPELINE
2020-05-20

MSN Laboratories Secures FDA Approval for Generic Oseltamivir Phosphate, Intensifying Market Competition

MSN Laboratories Private Limited received FDA approval for its Oseltamivir Phosphate generic capsules (ANDA212544) on May 20, 2020. This significant development introduces a new bioequivalent option in 30mg, 45mg, and 75mg strengths, enhancing supply chain diversity and competitive pricing for procurement directors. As an Indian API manufacturer, MSN's entry reinforces global generic supply dynamics.

CLINICAL & PIPELINE
2020-05-20

Cipla Secures FDA Approval for Generic Dihydroergotamine Mesylate Nasal Spray (ANDA212907)

Cipla USA Inc. received FDA approval for its generic DIHYDROERGOTAMINE MESYLATE NASAL spray (ANDA212907) on May 20, 2020, with a labeling update on September 12, 2023. This "AB" rated therapeutic equivalent product offers procurement directors a cost-effective alternative, intensifying competition in the nasal spray market. Supply chain VPs should anticipate pricing pressure, while business development executives can leverage increased market access for this critical medication.

CLINICAL & PIPELINE
2020-05-18

Alembic Pharmaceuticals Secures FDA Approval for Generic Clobetasol Propionate 0.05% Topical Shampoo

Alembic Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA213290) for Clobetasol Propionate 0.05% Topical Shampoo. This generic approval, granted on May 18, 2020, introduces a bioequivalent alternative into the market, signaling increased competition and potential cost efficiencies for procurement directors. Supply chain VPs should assess sourcing diversification, while regulatory affairs heads must monitor market shifts.

CLINICAL & PIPELINE
2020-05-14

Aurobindo Pharma Secures FDA Approval for Generic Albuterol Sulfate Oral Tablets, Intensifying Market Competition

Aurobindo Pharma Ltd. has received FDA approval for generic Albuterol Sulfate oral tablets (ANDA213657) on May 14, 2020. This expands generic options for respiratory care, driving cost competition. Procurement and supply chain leaders must assess Aurobindo's manufacturing stability, given its high-risk profile and history of recalls, to ensure reliable supply.

REGULATORY INTELLIGENCE
2020-05-13

Sandoz Infuvite Pediatric Recall: Sub-Optimal Vial Crimping Exposes Critical Container Integrity Risks

Sandoz Inc. initiated a Class II recall for 17,500 units of INFUVITE PEDIATRIC (Multiple Vitamins Injection) due to sub-optimal vial crimping. This FDA-terminated recall, impacting nationwide U.S. distribution, underscores the critical importance of container closure integrity in sterile pharmaceutical products. Procurement and regulatory teams must scrutinize packaging supplier quality and manufacturing process controls to mitigate similar supply chain disruptions.

CLINICAL & PIPELINE
2020-05-11

Unichem Pharmaceuticals Secures Multiple FDA Approvals for Generic Tramadol Hydrochloride, Bolstering Pain Management Supply

Unichem Pharmaceuticals (USA), Inc. has received multiple FDA approvals for its generic Tramadol Hydrochloride 50mg tablets, including the original ANDA approval in 2019 and numerous subsequent labeling and REMS updates through 2026. This reinforces the availability of a critical pain medication, impacting procurement strategies, regulatory compliance, and supply chain resilience for stakeholders in the global chemical and life sciences industry.

REGULATORY INTELLIGENCE
2020-05-06

B. Braun Medical Inc. Faces Class I Recall for Ceftazidime/Dextrose Due to High Molecular Weight Polymers

B. Braun Medical Inc. initiated a Class I recall for its Ceftazidime for Injection USP and Dextrose for Injection USP due to out-of-specification results for High Molecular Weight Polymers. This voluntary action, impacting 22,488 units nationwide, underscores critical quality control vulnerabilities in sterile injectables. Procurement and regulatory teams must scrutinize supplier stability data to mitigate patient safety and supply chain risks.

CLINICAL & PIPELINE
2020-05-05

ScieGen Pharms Strengthens Generic Metformin Hydrochloride Market with Diverse Tablet Portfolio

ScieGen Pharms has secured multiple approvals for its Abbreviated New Drug Application (ANDA203769) for generic Metformin Hydrochloride tablets, including original market entry in 2013 and subsequent manufacturing and labeling updates through 2020. This reinforces the competitive landscape for this essential oral antidiabetic, offering procurement directors diversified supply options across various strengths. Regulatory affairs teams should note the ongoing lifecycle management demonstrated by these approvals.

REGULATORY INTELLIGENCE
2020-04-29

Noven Therapeutics' DAYTRANA Recall: Defective Methylphenidate Transdermal System Impacts US Supply

Noven Therapeutics, LLC initiated a Class II recall for 7,957 boxes of DAYTRANA (methylphenidate transdermal system) due to a defective delivery system, specifically issues with mechanical peel and shear. This voluntary, firm-initiated recall, distributed nationwide in the US, highlights critical quality control challenges in transdermal drug delivery. The recall, D-1247-2020, was terminated on June 17, 2024.

REGULATORY INTELLIGENCE
2020-04-29

Lupin Pharmaceuticals Initiates Class II Recall for Subpotent Cefixime Oral Suspension: Critical Quality Failure Impacts US Market

Lupin Pharmaceuticals Inc. initiated a Class II voluntary recall for 4,518 bottles of Cefixime for Oral Suspension USP due to subpotency. This event, stemming from a stability study failure, highlights critical quality control vulnerabilities. Procurement, regulatory, and supply chain leaders must reassess supplier qualification and risk mitigation strategies to prevent similar disruptions and ensure patient safety.

REGULATORY INTELLIGENCE
2020-04-29

Yusef Manufacturing Laboratories Recalls SPF Lip Moisturizers Due to Superpotent Oxybenzone Levels

Yusef Manufacturing Laboratories, LLC faced an FDA Class II recall for SPF lip moisturizers containing up to 150% of the labeled Oxybenzone. This event, now terminated, highlights critical quality control failures in contract manufacturing. Procurement and regulatory teams must scrutinize supplier potency testing and formulation adherence to mitigate significant brand and consumer safety risks.

REGULATORY INTELLIGENCE
2020-04-29

Noven Therapeutics' Daytrana Methylphenidate Recall: Critical Defect in Transdermal Delivery System

Noven Therapeutics, LLC faced a Class II recall for its Daytrana (methylphenidate transdermal system) due to a defective delivery system failing mechanical peel and shear specifications. This nationwide US recall, initiated March 2020 and terminated June 2024, underscores critical quality control vulnerabilities in specialized drug delivery. Procurement and regulatory teams must scrutinize transdermal patch suppliers to mitigate supply chain risks and ensure patient safety.

CLINICAL & PIPELINE
2020-04-29

COREPHARMA's Generic LISINOPRIL ANDA Approval: Two Decades of Market Presence and Supply Chain Evolution

COREPHARMA secured US FDA approval for its generic LISINOPRIL tablets (ANDA076102) on September 30, 2002, marking a significant entry into the angiotensin-converting enzyme (ACE) inhibitor market. This approval, covering six strengths from 2.5MG to 40MG, has been followed by numerous labeling updates, demonstrating sustained regulatory compliance. The involvement of manufacturers like Heritage Pharmaceuticals and Exelan Pharmaceuticals underscores a robust, multi-entity supply chain for this essential medication, ensuring long-term market availability and cost-effectiveness for procurement and supply chain stakeholders.

CLINICAL & PIPELINE
2020-04-24

tobraDex: Decades of FDA Regulatory Management for a Type 3 New Dosage Form

The FDA's 1988 approval of tobraDex as a Type 3 New Dosage Form, application 50-616, highlights the enduring regulatory lifecycle of mature pharmaceutical products. Subsequent decades of supplemental approvals for labeling and manufacturing underscore critical ongoing compliance demands. This necessitates robust supply chain and regulatory strategies for long-standing market assets.

REGULATORY INTELLIGENCE
2020-04-22

Filltech USA Recalls Dermatone Sunscreen Nationwide Due to Microbial Contamination, Highlighting Supply Chain Vulnerabilities

Filltech USA, LLC initiated a nationwide Class II recall of Dermatone Sunscreen Lotion due to microbial contamination (yeast and bacteria). This event, impacting 4790 tottles and 20,403 tubes, underscores critical quality control and supply chain risks for procurement and regulatory affairs teams. Proactive supplier qualification and robust quality assurance are paramount to mitigate similar disruptions.

REGULATORY INTELLIGENCE
2020-04-22

Aurobindo Pharma USA Inc. Terminates Class II Recall of Gabapentin Capsules Due to CGMP Water Leakage

Aurobindo Pharma USA Inc. has terminated its Class II recall of Gabapentin Capsules, USP 100mg, initiated due to critical CGMP deviations, specifically water leakage in a manufacturing area. This event, affecting 26,625 units distributed nationwide, underscores the imperative for robust supplier qualification and continuous regulatory oversight in pharmaceutical supply chains.

REGULATORY INTELLIGENCE
2020-04-22

FDA Class II Recall: H J Harkins Company's cGMP Deviations Impact Acetaminophen and Codeine Phosphate Supply

H J Harkins Company Inc dba Pharma Pac faced an FDA Class II recall for 9,000 units of Acetaminophen and Codeine Phosphate 300/30 mg tablets due to cGMP deviations. This terminated recall, initiated in 2020, underscores critical supply chain vulnerabilities in pharmaceutical repackaging. Procurement and regulatory teams must enhance due diligence for all partners, ensuring robust quality systems to mitigate disruption risks for essential opioid analgesics distributed in California and Arizona.

REGULATORY INTELLIGENCE
2020-04-22

FDA Recall: B & B Pharmaceuticals' Estradiol Contaminated with Teflon, Highlighting cGMP Lapses

B & B Pharmaceuticals, Inc. initiated a nationwide Class II recall of Estradiol, USP (Non-Micronized) (Hemihydrate) due to Teflon contamination introduced during production. This event underscores critical cGMP deviations impacting product integrity and patient safety. Procurement and regulatory teams must reassess supplier qualification and supply chain vigilance to mitigate risks associated with active pharmaceutical ingredient (API) quality failures.

REGULATORY INTELLIGENCE
2020-04-22

The Medicine Shoppe Pharmacy's Bi-Est Cream Recall Highlights Critical Compounding Processing Control Gaps

The Medicine Shoppe Pharmacy's Class II recall of Bi-Est cream due to 'Lack of Processing Control' in Port Charlotte, Florida, underscores critical quality assurance vulnerabilities in compounded pharmaceuticals. This event signals that procurement and regulatory teams must enhance vigilance over small-scale and local suppliers to mitigate patient safety and supply chain risks.

REGULATORY INTELLIGENCE
2020-04-22

FDA Class II Recall: NBMA Impurity in Losartan Potassium API Impacts Golden State Medical Supply

Golden State Medical Supply Inc. faced a Class II FDA recall for Losartan Potassium Tablets due to N-nitroso-N-methyl-4-aminobutryric Acid (NBMA) impurity in the API. This event underscores critical supply chain vulnerabilities in API quality control, demanding enhanced due diligence from procurement and stringent CGMP adherence to mitigate regulatory and patient safety risks across the pharmaceutical industry.

REGULATORY INTELLIGENCE
2020-04-22

FDA Class II Recall: The Medicine Shoppe Pharmacy Cites Processing Control Lapses for Hormone Compound

The Medicine Shoppe Pharmacy initiated a Class II recall for its Bi-Est/Progesterone/Testosterone compounded hormone product due to a critical 'Lack of Processing Control' at its Port Charlotte, FL facility. This event, terminated in December 2022, underscores the FDA's heightened focus on quality assurance in compounding pharmacies. Decision-makers must reassess supplier qualification protocols and internal oversight for compounded pharmaceutical sourcing to mitigate regulatory and supply chain risks.

CLINICAL & PIPELINE
2020-04-20

Gland Pharma Secures Latest Labeling Approval for Generic Levetiracetam Injection (ANDA206880), Bolstering Supply Chain Stability

Gland Pharma Limited has secured a recent labeling approval for its generic Levetiracetam Injection (ANDA206880), with an effective date of March 26, 2025. This intravenous antiepileptic drug, also manufactured by Dr. Reddy's Laboratories Inc and Sagent Pharmaceuticals, reinforces supply chain resilience and cost-effective access for critical neurological care. Procurement and regulatory teams should note the ongoing product lifecycle management.

CLINICAL & PIPELINE
2020-04-20

FDA Application 021427: A Decade of Sustained Supplemental Approvals and Regulatory Evolution

The FDA has approved numerous supplemental applications for application number 021427, spanning from 2007 to 2021. This consistent regulatory activity, encompassing both efficacy and labeling updates, underscores the continuous lifecycle management required for established pharmaceutical products. For decision-makers, this highlights the critical need for robust regulatory affairs and quality management systems to maintain market access and adapt to evolving clinical data and safety profiles.

REGULATORY INTELLIGENCE
2020-04-15

Avet Pharmaceuticals' Class I Recall of Tetracycline HCL Capsules Signals Critical Quality Control Gaps

Avet Pharmaceuticals initiated a Class I recall for 4,444 bottles of Tetracycline HCL Capsules, 250 mg, due to failed dissolution specifications during long-term testing. This event, terminated in August 2022, highlights significant quality control deficiencies impacting drug efficacy and patient safety, necessitating immediate action for procurement and regulatory teams to reassess supplier quality assurance protocols for essential generic antibiotics.

REGULATORY INTELLIGENCE
2020-04-15

FDA Class II Recall: Herbal Doctor Remedies' Detoxin-S Deemed Unapproved and Misbranded

Herbal Doctor Remedies faced an FDA Class II recall for Detoxin-S 500mg Capsules due to CGMP deviations, rendering them unapproved new drugs and misbranded. This voluntary, firm-initiated recall, active from March 2020 to January 2024, impacted online and international markets, highlighting critical compliance risks for procurement and regulatory teams globally.

REGULATORY INTELLIGENCE
2020-04-15

FDA Class II Recall: Innovative Compounding Pharmacy's Testosterone Cypionate Lacked Sterility Assurance

Innovative Intrathecal Solutions, Inc. dba Innovative Compounding Pharmacy initiated a Class II recall for multiple lots of Testosterone Cypionate In Sesame Oil 200mg/ml injectable due to a lack of sterility assurance. This Murrieta, CA-based firm's voluntary action, impacting patients in CA, ME, and TX, underscores critical quality control vulnerabilities in compounded sterile preparations. Procurement and regulatory teams must scrutinize supplier sterility protocols to mitigate supply chain risks.

REGULATORY INTELLIGENCE
2020-04-15

PharMEDium Services' ePHEDrine Sulfate Recall: Sterility Lapses Expose Critical Supply Chain Risks

PharMEDium Services, LLC initiated a Class II recall of 46 lots, including ePHEDrine Sulfate, due to critical sterility assurance failures. This nationwide distribution event, recall number D-1090-2020, highlights significant risks for procurement and regulatory teams relying on compounded sterile products. The termination of this recall on February 14, 2025, underscores the long-term impact of such quality lapses on patient safety and supply chain integrity.

REGULATORY INTELLIGENCE
2020-04-15

FDA Class I Recall: Avet Pharmaceuticals' Tetracycline HCL Capsules Fail Dissolution

Avet Pharmaceuticals, Inc. faced a Class I FDA recall for 17,524 bottles of Tetracycline HCL Capsules, USP, 500 mg, due to failed dissolution specifications during long-term testing. This nationwide recall, initiated on March 23, 2020, underscores critical quality control requirements for generic pharmaceuticals. Procurement and regulatory teams must assess supplier stability data and ensure robust quality agreements to mitigate supply chain disruptions.

CLINICAL & PIPELINE
2020-04-13

Medtech Products' TAGAMET HB (Cimetidine) Secures Enduring Market Position Through Continuous FDA Approvals

Medtech Products' TAGAMET HB (Cimetidine) achieved a pivotal Type 8 Partial Rx to OTC Switch approval from the FDA on June 19, 1995. This strategic move established Cimetidine as a key over-the-counter histamine H2 receptor antagonist. Subsequent, continuous manufacturing (CMC) and labeling approvals, including a May 2022 update, underscore Medtech's commitment to regulatory compliance and supply chain stability, crucial for sustained market presence.

CLINICAL & PIPELINE
2020-04-10

Teva Pharmaceuticals Secures FDA Labeling Approval for Discontinued Oxaliplatin Injectable (NDA022160)

Teva Pharmaceuticals has received FDA approval for a supplemental labeling application (submission 16) for its Oxaliplatin injectable (NDA022160) on October 31, 2024. Despite this regulatory update, both 50MG/10ML and 100MG/20ML strengths of Teva's Oxaliplatin are officially listed as "Discontinued" by the FDA, indicating no active market presence for this specific product.

REGULATORY INTELLIGENCE
2020-04-08

FDA Class II Recall: Gentamicin Sterility Failure at The Medicine Shoppe Pharmacy Highlights Compounding Risks

The Medicine Shoppe Pharmacy initiated a Class II recall (D-1072-2020) for Gentamicin 80mg/60 mL Irrigation due to lack of sterility assurance. This Florida-centric recall, terminated December 2022, underscores critical quality control vulnerabilities in local pharmaceutical compounding. Procurement and regulatory teams must scrutinize sterility protocols across all suppliers, regardless of scale, to mitigate patient safety risks.

CLINICAL & PIPELINE
2020-04-06

Zydus Pharmaceuticals Secures FDA Approval for Generic Succinylcholine Chloride Injection

Zydus Pharmaceuticals received FDA approval for its generic Succinylcholine Chloride injection (ANDA209467) on May 4, 2018. This approval, with an "AP" therapeutic equivalence rating, designates Zydus's product as a reference standard, enhancing market competition and supply chain resilience for this critical neuromuscular blocker. This offers procurement and supply chain leaders a new, therapeutically equivalent option.

REGULATORY INTELLIGENCE
2020-04-01

Glaxosmithkline Consumer Healthcare Holdings Recalls Advil Allergy & Congestion Relief Over Critical Labeling Omissions

Glaxosmithkline Consumer Healthcare Holdings initiated a Class II recall for 471,024 blisters of Advil Allergy & Congestion Relief due to missing safety warnings on the Drug Facts Panel. This voluntary action, terminated in October 2021, underscores critical labeling compliance risks for OTC products. Procurement and regulatory teams must scrutinize supplier adherence to FDA regulations to prevent market disruptions and safeguard brand integrity.

REGULATORY INTELLIGENCE
2020-04-01

Jubilant Draximage Inc. Faces FDA Class II Recall for DRAXIMAGE DTPA Due to Stability Failures

Jubilant Draximage Inc. initiated a Class II recall for 473 kits of DRAXIMAGE DTPA (Technetium Tc 99m Pentetate Injection) due to failed stability specifications. This FDA-monitored action, impacting U.S. distribution from their Canadian facility, highlights critical quality control needs for radiopharmaceuticals. Procurement and regulatory teams must scrutinize supplier stability data to mitigate supply chain risks.

REGULATORY INTELLIGENCE
2020-04-01

FDA Terminates Class II Recall for Matthew 7:25 Inc dba Thrive Pharmacy's Subpotent Buprenorphine Troches

Matthew 7:25 Inc dba Thrive Pharmacy faced an FDA Class II recall for subpotent Buprenorphine Black Cherry 2 mg Troches, lot 191217A, distributed in Florida. This voluntary, firm-initiated action, terminated in June 2023, highlights critical quality control failures. Procurement and regulatory teams must enhance due diligence for compounded products to mitigate efficacy and safety risks.

REGULATORY INTELLIGENCE
2020-04-01

Glaxosmithkline Consumer Healthcare Holdings Initiates Class II Recall of Advil Liqui-Gel Minis Due to Labeling Omission

Glaxosmithkline Consumer Healthcare Holdings voluntarily recalled 446,628 bottles of Advil Liqui-Gel Minis (Ibuprofen 200 mg) across the U.S. and Puerto Rico. This Class II recall, initiated March 16, 2020, was due to the omission of critical safety warnings on the Drug Facts Panel. The event highlights the imperative for rigorous quality control in labeling to prevent market disruptions and ensure patient safety.

REGULATORY INTELLIGENCE
2020-04-01

Nostrum Laboratories Inc. Faces FDA Scrutiny Over Theophylline CGMP Deviations and Labeling Errors

Nostrum Laboratories Inc. initiated a Class II recall of Theophylline (Anhydrous) Extended-Release Tablets due to critical CGMP deviations and incorrect labeling. This event highlights significant quality control failures at their Kansas City, MO facility, impacting supply chain reliability. Decision-makers must assess supplier risk and reinforce robust quality assurance protocols to mitigate similar disruptions and ensure regulatory compliance.

REGULATORY INTELLIGENCE
2020-03-25

FDA Class III Recall: Par Pharmaceutical's Prednisone Labeling Error Impacts Nationwide Supply

Par Pharmaceutical Inc. initiated a nationwide Class III recall of 13,008 bottles of Prednisone Tablets, USP 5 mg, due to an incorrect expiration date. This voluntary action, terminated in April 2021, highlights critical labeling quality control gaps. Procurement and regulatory teams must scrutinize supplier quality systems, especially for high-volume generic corticosteroids like Prednisone, to mitigate supply chain disruption and compliance risks.

CLINICAL & PIPELINE
2020-03-25

Sandoz Secures Latest FDA Labeling Approval for Generic Dorzolamide Hydrochloride Ophthalmic Solution

Sandoz Inc. has received a supplemental FDA approval on January 23, 2023, for labeling updates concerning its generic Dorzolamide Hydrochloride ophthalmic solution (ANDA078981). This regulatory action, following the original 2009 approval, reinforces Sandoz's commitment to product lifecycle management and compliance in the competitive glaucoma treatment market. For procurement and regulatory teams, this signifies continued market stability and validated product information, ensuring reliable supply and adherence to evolving standards.

REGULATORY INTELLIGENCE
2020-03-25

Fresenius Medical Care's Sodium Chloride Recall Highlights Critical CGMP Sterilization Risks for Injectables

Fresenius Medical Care Holdings, Inc. faced an FDA Class II recall for 32,592 bags of Sodium Chloride 0.9% Injection, USP, due to critical CGMP deviations in sterilization. This event, now terminated, underscores persistent risks in aseptic processing. Procurement and regulatory teams must scrutinize supplier sterilization protocols and quality systems to mitigate supply chain disruptions and ensure patient safety, especially for essential injectables.

REGULATORY INTELLIGENCE
2020-03-25

Perrigo's Ranitidine Recall: NDMA Contamination Exposes CGMP Lapses and Supply Chain Risks

Perrigo Company PLC initiated a nationwide recall of Ranitidine tablets due to CGMP deviations and potential N-nitrosodimethylamine (NDMA) contamination. This event highlights critical quality control vulnerabilities and broad supply chain exposure across multiple retail brands. Decision-makers must reassess supplier qualification, impurity testing, and diversification strategies to mitigate similar regulatory and commercial risks in the pharmaceutical sector.

REGULATORY INTELLIGENCE
2020-03-25

Sun Pharma's Doxycycline Recall: FDA Cites CGMP Deviations, Highlighting Generic Drug Supply Risks

Sun Pharmaceutical Industries, Inc. faced a Class II recall of Doxycycline Capsules, USP, 75 mg, due to significant CGMP deviations at its manufacturing site. This voluntary action, impacting 624 bottles distributed nationwide, underscores critical quality control vulnerabilities. Procurement and regulatory teams must scrutinize supplier compliance, especially for generic tetracycline-class drugs, to mitigate supply chain disruptions and ensure product integrity.

REGULATORY INTELLIGENCE
2020-03-25

Mylan Pharmaceuticals' Sotalol HCL Recall: Metal Particulate Contamination Impacts US Supply

Mylan Pharmaceuticals initiated a Class II recall for Sotalol HCL Tablets (80 mg) due to metal particulate contamination from its Morgantown, WV facility. This event, impacting 300 bottles nationwide, underscores critical quality control vulnerabilities. Procurement and supply chain leaders must reassess supplier qualification and risk mitigation strategies for essential cardiovascular drugs.

REGULATORY INTELLIGENCE
2020-03-25

FDA Class I Recall: Med Man Distribution's Bow & Arrow Supplement Contained Undeclared Sildenafil

Med Man Distribution, Inc. initiated a Class I recall of its Bow & Arrow dietary supplement due to undeclared sildenafil, identified by FDA analysis. This event, terminated on October 17, 2023, underscores critical regulatory and supply chain risks for companies distributing products without proper drug approvals, impacting nationwide US markets and demanding enhanced due diligence.

REGULATORY INTELLIGENCE
2020-03-18

American Health Packaging's Ranitidine Recall: NDMA Contamination Exposes Critical CGMP Failures

American Health Packaging's recall of Ranitidine Tablets, USP, 150 mg, due to N-Nitrosodimethylamine (NDMA) exceeding FDA limits highlights critical Current Good Manufacturing Practice (CGMP) deviations. This event underscores the persistent challenge of nitrosamine impurities in the pharmaceutical supply chain, demanding enhanced vigilance from procurement, regulatory, and supply chain leaders to mitigate widespread quality and compliance risks.

REGULATORY INTELLIGENCE
2020-03-18

Redline Pharmacy Solutions Recalls Intrathecal Morphine Sulfate Due to Critical Processing Control Lapses

Redline Pharmacy Solutions initiated a Class II recall of intrathecal Morphine Sulfate due to a critical 'Lack of Processing Controls'. This event, impacting patients in Nebraska, underscores the imperative for robust quality management in compounding pharmacies. Procurement and regulatory teams must scrutinize supplier quality systems for high-risk medications, even from regional distributors, to mitigate patient safety and supply chain risks.

REGULATORY INTELLIGENCE
2020-03-11

Fusion IV Pharmaceuticals' Selenium Injection Recall Highlights Critical Sterility Assurance Risks

Fusion IV Pharmaceuticals, dba Axia Pharmaceutical, faced a Class II recall for its Selenium Injection due to lack of sterility assurance. This event, lasting nearly four years, underscores significant supply chain and regulatory risks for procurement directors and regulatory affairs heads, emphasizing the critical need for robust quality systems in sterile injectable manufacturing across the U.S. and international markets.

REGULATORY INTELLIGENCE
2020-03-11

FDA Class II Recall: Fusion IV Pharmaceuticals' Polidocanol Injection Lacked Sterility Assurance

Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical initiated a Class II recall for its Polyoxyl Lauryl Ether (Polidocanol) Injection due to a lack of sterility assurance. This nationwide U.S. and international recall, terminated in December 2023, highlights critical supply chain and regulatory risks for procurement and regulatory affairs teams sourcing injectable pharmaceuticals.

REGULATORY INTELLIGENCE
2020-03-11

Pfizer's Elelyso Recall: Sterility Assurance Failure Impacts Global Supply of Taliglucerase Alfa

Pfizer Inc. initiated a Class II recall of 24,714 vials of Elelyso (taliglucerase alfa) due to loose vial crimps compromising sterility. This voluntary action, impacting US and international markets, highlights critical packaging quality control failures. For decision-makers, it underscores the imperative for robust supplier qualification and vigilant oversight to mitigate supply chain disruptions and ensure product integrity.

CLINICAL & PIPELINE
2020-03-05

Genus Secures FDA Approval for Oral Potassium Chloride Solution (NDA208019)

Genus Lifesciences Inc. secured FDA approval for its Potassium Chloride oral solution (NDA208019) on August 19, 2015. This Type 7 approval formalized market access for Genus's 10MEQ, 15MEQ, 20MEQ, and 40MEQ formulations, an essential electrolyte. Subsequent labeling updates in 2019 and 2020 reinforce regulatory compliance. This event impacts procurement strategies and competitive dynamics in the established electrolyte market.

REGULATORY INTELLIGENCE
2020-03-04

FDA Class I Recall: Taro Pharmaceuticals' Phenytoin Oral Suspension Faces Critical Resuspension Failure

Taro Pharmaceuticals U.S.A., Inc. initiated a Class I recall for Phenytoin Oral Suspension USP due to critical resuspension problems, impacting 29,172 bottles nationwide. This event, now terminated, underscores significant quality control risks for procurement and regulatory teams, necessitating rigorous supplier due diligence and robust supply chain resilience strategies for anti-epileptic agents.

REGULATORY INTELLIGENCE
2020-02-26

American Health Packaging Desmopressin Acetate Recall: GMP Deviation Exposes Packaging Quality Risks

American Health Packaging initiated a Class II recall of 1,879 cartons of Desmopressin Acetate Tablets nationwide due to missing desiccants, a critical GMP deviation. This event, terminated in August 2022, underscores the imperative for robust quality control in pharmaceutical packaging. Procurement and regulatory teams must scrutinize supplier quality systems to mitigate supply chain disruptions and ensure product integrity.

REGULATORY INTELLIGENCE
2020-02-26

NCS Healthcare Glycopyrrolate Recall Highlights Critical Impurity Control Failures for Institutional Supply

NCS Healthcare of Kentucky Inc initiated a Class II recall for 6,929 blister cards of Glycopyrrolate Tabs, USP, 1 mg, due to high out-of-specification results for individual unknown impurities. This event, terminated on February 19, 2021, signals critical quality control deficiencies impacting institutional pharmaceutical supply chains. Procurement and regulatory teams must reassess supplier qualification and product quality assurance protocols for similar drug products.

CLINICAL & PIPELINE
2020-02-25

Teva Pharmaceuticals' Sildenafil Citrate 20mg ANDA: Approval, Discontinuation, and Supply Chain Implications

Teva Pharmaceuticals' ANDA for Sildenafil Citrate 20mg tablets received FDA approval on January 7, 2013, but the product has since been discontinued. This event highlights critical considerations for pharmaceutical procurement and supply chain resilience. Decision-makers must analyze market dynamics that lead to generic discontinuations, assess potential supply chain vulnerabilities, and ensure robust alternative sourcing strategies for essential molecules like Sildenafil Citrate.

CLINICAL & PIPELINE
2020-02-21

Macleods Pharma's Generic Losartan/Hydrochlorothiazide Approval: A Decade of Market Impact and Regulatory Diligence

Macleods Pharmaceuticals Limited secured FDA approval for its generic Losartan Potassium and Hydrochlorothiazide (ANDA202289) on August 9, 2012. This significantly expanded access to an essential hypertension treatment, intensifying market competition and driving price adjustments. The subsequent decade of labeling updates underscores the continuous regulatory commitment required for generic pharmaceutical products, impacting procurement and regulatory strategies.

CLINICAL & PIPELINE
2020-02-21

Accord Healthcare Secures FDA Approval for Zoledronic Acid ANDA205279, Intensifying Generic Competition

Accord Healthcare secured FDA approval for its Zoledronic Acid ANDA205279 on November 28, 2016, marking a significant generic entry. This approval for the intravenous injectable strengthens Accord's market position and intensifies competition for existing Zoledronic Acid suppliers. Procurement directors should leverage this to optimize sourcing strategies and drive cost efficiencies, while regulatory teams note ongoing labeling updates from Accord Healthcare.

REGULATORY INTELLIGENCE
2020-02-19

FDA Class I Recall: Taro Pharmaceuticals' Lamotrigine Contaminated with Enalapril Maleate

Taro Pharmaceuticals U.S.A., Inc. initiated a Class I recall of Lamotrigine Tablets 100 mg due to enalapril maleate cross-contamination. This critical regulatory action, terminated February 2024, underscores severe quality control failures impacting patient safety and supply chain integrity. Procurement and regulatory teams must scrutinize supplier quality systems to mitigate similar high-risk events.

REGULATORY INTELLIGENCE
2020-02-19

FDA Class II Recall: Efficient Laboratories' Rompe Pecho MAX Multi Symptoms Due to Microbial Contamination Signals Heightened Regulatory Scrutiny

Efficient Laboratories, Inc. initiated a Class II recall of 4,080 bottles of Rompe Pecho MAX Multi Symptoms due to microbial contamination. This event, terminated in October 2020, underscores critical compliance risks for non-sterile products. Procurement and regulatory teams must scrutinize supplier quality systems to mitigate similar supply chain disruptions and ensure patient safety.

REGULATORY INTELLIGENCE
2020-02-19

AuroMedics Pharma LLC's Class II Recall of Amoxicillin/Clavulanate Potassium: Supply Chain Contamination Risks

AuroMedics Pharma LLC initiated a Class II recall of Amoxicillin and Clavulanate Potassium tablets due to a nylon cable tie foreign substance. This event, involving a product manufactured by Aurobindo Pharma Limited, underscores critical quality control vulnerabilities in generic pharmaceutical supply chains. Procurement and regulatory teams must enhance due diligence and diversify sourcing for essential antibiotics to mitigate disruption.

REGULATORY INTELLIGENCE
2020-02-19

FDA Class II Recall: Contract Pharmacal's Acetaminophen Commingling Exposes OTC Supply Chain Risks

Contract Pharmacal Corporation faced an FDA Class II recall (D-0858-2020) for Major Extra Strength Acetaminophen Tablets due to commingling with a prenatal supplement. This event, now terminated, highlights critical quality control vulnerabilities in high-volume OTC manufacturing. Procurement directors and supply chain VPs must reinforce supplier qualification and audit processes to mitigate patient safety risks and ensure product integrity across their pharmaceutical portfolios.

CLINICAL & PIPELINE
2020-02-14

LUPIN and SOLA Pharmaceuticals Secure Latest FDA Labeling Approval for Generic Diclofenac Sodium 1.5% Topical Solution

LUPIN, through its manufacturing partner SOLA Pharmaceuticals, has secured another FDA supplemental labeling approval for its generic Diclofenac Sodium 1.5% Topical Solution (ANDA204132) on 2024-11-21. This marks the fifth such approval since the original ANDA in 2015, underscoring continuous regulatory engagement for this key anti-inflammatory. For procurement and regulatory teams, these updates signal ongoing product lifecycle management and potential market adjustments.

REGULATORY INTELLIGENCE
2020-02-12

Unichem Pharmaceuticals Recalls Clonidine HCl: Benzophenone Migration from Packaging Exposes Supply Chain Vulnerabilities

Unichem Pharmaceuticals (USA), Inc. initiated a Class III recall of 19.16 million units of Clonidine Hydrochloride tablets due to Benzophenone migration from container labels. This event underscores critical risks in packaging material quality and supplier oversight. Procurement and regulatory teams must enhance vendor qualification and impurity testing protocols to safeguard product integrity and patient safety.

REGULATORY INTELLIGENCE
2020-02-12

FDA Class II Recall: Ascend Laboratories' Olmesartan Medoxomil Due to Unapproved API Source Change

Ascend Laboratories LLC initiated a Class II recall of Olmesartan Medoxomil Tablets 20 mg due to cGMP deviations. The product was released with an unapproved alternate API source, highlighting critical regulatory and supply chain risks. This event underscores the imperative for robust change control and validated API sourcing strategies to maintain market access and patient safety.

REGULATORY INTELLIGENCE
2020-02-12

FDA Terminates Spectrum Laboratory Products' Ranitidine HCl Recall Amid NDMA Contamination

The FDA has terminated Spectrum Laboratory Products' Class II recall of Ranitidine Hydrochloride (powder), USP, initiated due to NDMA impurity and CGMP deviations. This event, impacting US, Canadian, and UAE markets, underscores persistent nitrosamine risks in API supply chains. Procurement and regulatory teams must enhance supplier vetting and analytical testing to mitigate future disruptions from similar quality failures.

CLINICAL & PIPELINE
2020-02-10

Hospira's Morphine Sulfate: 2020 Labeling Approval Reinforces Ongoing Regulatory Compliance for Generic Analgesics

Hospira, Inc. received a U.S. Food and Drug Administration (FDA) supplemental approval on February 10, 2020, for a labeling update to its generic Morphine Sulfate injectable (ANDA073509). This regulatory action for the long-standing analgesic, originally approved in 1992, underscores ongoing compliance requirements for mature pharmaceutical products. Decision-makers must recognize the continuous need for robust regulatory affairs and supply chain management to maintain market access and product integrity.

CLINICAL & PIPELINE
2020-02-07

Actavis Labs FL Inc.'s Ramelteon Generic: Navigating Labeling Updates and Market Access for Insomnia Treatment

Actavis Labs FL Inc. secured its initial generic approval for RAMELTEON (ANDA091610) in August 2015, followed by significant labeling updates in 2020 and 2023. This highlights the ongoing regulatory demands for generic manufacturers and the strategic importance of maintaining product compliance and supply chain efficiency in the competitive melatonin receptor agonist market for insomnia.

REGULATORY INTELLIGENCE
2020-02-05

FDA Class II Recall: Pharmaceutical Associates' Subpotent Nystatin Oral Suspension Impacts US Supply

Pharmaceutical Associates, Inc. initiated a Class II recall of Nystatin Oral Suspension due to subpotency, affecting 6,288 bottles distributed nationwide. This event highlights critical quality control vulnerabilities in pharmaceutical manufacturing, demanding immediate attention from procurement and regulatory teams to ensure product efficacy and patient safety within the US market.

REGULATORY INTELLIGENCE
2020-02-05

FDA Class II Recall: MPRX, Inc. dba Medical Park Pharmacy Recalls Squaric Acid Solution Over Expired Components

MPRX, Inc. dba Medical Park Pharmacy initiated a Class II recall for one bottle of Squaric Acid 0.1% Topical Solution (Clinic) on December 18, 2019. The recall, terminated December 13, 2022, stemmed from compounding with expired components and labeling deficiencies. This highlights the critical need for rigorous quality control and adherence to Good Manufacturing Practices, even for small-scale compounding operations, to mitigate patient safety risks and regulatory penalties.

CLINICAL & PIPELINE
2020-02-04

Lupin Secures Labeling Approval for Generic Contraceptive VYFEMLA Amidst Ongoing Quality Scrutiny

Lupin Pharmaceuticals secured supplemental labeling approval for its generic oral contraceptive, VYFEMLA (NORETHINDRONE AND ETHINYL ESTRADIOL), on April 29, 2022. This regulatory update ensures continued market access for the AB-rated product. However, procurement and supply chain leaders must consider Lupin's 'watch' risk band and history of quality recalls, necessitating enhanced supplier due diligence and diversified sourcing strategies for critical generic molecules.

REGULATORY INTELLIGENCE
2020-01-29

H J Harkins Pharma Pac Ranitidine Recall: NDMA Impurity Exposes Critical CGMP Lapses and Supply Chain Risks

H J Harkins Company Inc dba Pharma Pac initiated a Class II recall of Ranitidine 150 mg Tablets due to NDMA impurity and CGMP deviations. This event, impacting distribution in CA, FL, NC, and SC, underscores persistent quality control challenges in pharmaceutical manufacturing and demands rigorous supply chain vigilance from industry leaders.

REGULATORY INTELLIGENCE
2020-01-29

Hikma Pharmaceuticals Recalls Methylprednisolone Sodium Succinate Due to Critical Labeling Error

Hikma Pharmaceuticals USA Inc. initiated a Class III recall of methylPREDNISolone Sodium Succinate for Injection due to incorrect reconstitution instructions on vial labels. This regulatory event highlights critical quality control vulnerabilities, necessitating immediate review of supply chain integrity and internal labeling protocols for procurement and regulatory affairs teams to mitigate patient safety risks and ensure compliance.

CLINICAL & PIPELINE
2020-01-27

Alembic Pharmaceuticals Strengthens Generic Dermatology Portfolio with FDA Approval for Clobetasol Propionate Cream

Alembic Pharmaceuticals secured FDA approval for its generic Clobetasol Propionate 0.05% Cream (ANDA213291) on January 27, 2020. This strengthens Alembic's dermatological footprint, following a shampoo formulation approval, intensifying competition for existing suppliers. Procurement directors should leverage this for cost savings, while supply chain VPs note Alembic's low-risk manufacturing profile, enhancing market access for this high-potency corticosteroid.

CLINICAL & PIPELINE
2020-01-24

FDA Grants Priority Efficacy Approval for Application 202293, Signaling Expanded Clinical Utility

The FDA has granted a Priority Review approval for Efficacy Supplement 31 to application 202293 on June 12, 2024. This significant regulatory milestone indicates an expansion of the product's approved clinical utility. Decision-makers must assess the implications of this efficacy update on market dynamics, competitive positioning, and future supply chain requirements for this undisclosed therapeutic.

CLINICAL & PIPELINE
2020-01-24

Merck's SEGLUROMET: Strategic Implications of a Type 4 New Combination Approval and Ongoing Labeling Updates for Diabetes Management

Merck Sharp & Dohme LLC's SEGLUROMET, a fixed-dose combination of Ertugliflozin and Metformin Hydrochloride, received its original Type 4 New Combination approval from the FDA on December 19, 2017. This strategic approval, coupled with continuous labeling updates, including a forthcoming one in December 2024, underscores Merck's commitment to the Type 2 Diabetes market and presents critical considerations for pharmaceutical supply chain and regulatory affairs.

REGULATORY INTELLIGENCE
2020-01-22

AVKARE Inc. Dutasteride Recall: Impurity Failures Highlight Critical Supply Chain Vulnerabilities

AVKARE Inc. initiated a Class II recall of 3,989 cartons of Dutasteride Capsules, 0.5 mg, due to high out-of-specification impurity levels. This nationwide U.S. distribution event, terminated in 2021, underscores the critical need for robust quality control and diversified sourcing strategies for procurement directors and supply chain VPs to mitigate disruption and ensure patient safety.

REGULATORY INTELLIGENCE
2020-01-22

FDA Class II Recall: Assurance Infusion's LIPO B Sterility Breach Impacts US Supply Chain

Assurance Infusion initiated a Class II recall (D-0749-2020) for its LIPO B product due to a critical lack of sterility assurance. This Houston, TX-based manufacturer's voluntary action, affecting nationwide U.S. distribution, highlights persistent quality control challenges in specialty pharmaceuticals. The recall, active from December 2019 to October 2021, underscores the imperative for robust supplier qualification and stringent sterility protocols to mitigate supply chain risks.

REGULATORY INTELLIGENCE
2020-01-22

McGuff Compounding Pharmacy's Lipoic Acid Injection Recall: Critical Lessons for Sterile Compounding Supply Chains

McGuff Compounding Pharmacy Services, Inc. initiated a Class II recall for 146 vials of Lipoic Acid Injection due to particulate matter. This event, now terminated, underscores persistent quality control challenges in sterile compounding. Procurement and regulatory teams must rigorously vet suppliers to mitigate patient safety risks and ensure supply chain integrity for critical compounded injectables.

REGULATORY INTELLIGENCE
2020-01-22

Assurance Infusion Initiates Nationwide Class II Recall of BUP/SUF Injection Due to Sterility Assurance Lapses

Assurance Infusion has executed a Class II nationwide recall of its BUP 20MG/SUF 1000MCG/ML INJ in 20 mL syringes, Lot 12172019@10, due to critical lack of sterility assurance. This event, initiated December 20, 2019, and terminated October 27, 2021, underscores significant risks in parenteral drug manufacturing. Procurement and regulatory teams must scrutinize compounding pharmacy quality systems to mitigate supply chain vulnerabilities and patient safety risks.

REGULATORY INTELLIGENCE
2020-01-22

Sigan Industries Inc. Recalls 11,004 Bottles of Eczema Skin Relief Lotion Due to Microbial Contamination

Sigan Industries Inc., based in Brampton, Canada, initiated a Class III recall of 11,004 bottles of Eczema Skin Relief Lotion due to microbial contamination. This voluntary, firm-initiated action, terminated in August 2022, highlights critical quality control challenges for non-sterile topical products. Procurement and regulatory teams must scrutinize supplier quality systems to mitigate similar supply chain disruptions and ensure product safety.

REGULATORY INTELLIGENCE
2020-01-22

Motto International Corp's Class I Recall: Undeclared Tadalafil in Unapproved Drug Exposes Critical Supply Chain Risks

Motto International Corp's Class I recall of Bull Platinum 30000 Capsules highlights critical regulatory non-compliance. The FDA found the product, distributed in Texas, contained undeclared tadalafil and was marketed without required NDA/ANDA approval. This event underscores the imperative for robust vendor qualification and rigorous analytical testing within pharmaceutical supply chains, particularly for products lacking transparent regulatory pathways, to mitigate significant health and business risks.

REGULATORY INTELLIGENCE
2020-01-22

Sun Pharma Recalls Testosterone Cypionate Due to cGMP Deviations, Impacting US Supply

Sun Pharmaceutical Industries, Inc. initiated a Class II recall (D-0787-2020) of Testosterone Cypionate for Injection, USP, distributed across the US. The action stemmed from cGMP deviations, as released lots were manufactured under conditions similar to a rejected OOS lot. This event, terminated in August 2020, underscores critical supply chain and quality assurance challenges for procurement and regulatory leaders.

CLINICAL & PIPELINE
2020-01-21

Dr. Reddy's Laboratories' Divalproex Sodium ANDA: A Decade of Sustained Generic Market Presence and Regulatory Activity

Dr. Reddy's Laboratories Ltd. secured its Abbreviated New Drug Application (ANDA) for Divalproex Sodium (ANDA078979) on January 23, 2009, establishing a long-standing presence in the generic market. This approval, followed by numerous labeling supplements, underscores the mature competitive landscape and the continuous regulatory compliance demands for this oral prescription drug, impacting procurement and regulatory strategies.

REGULATORY INTELLIGENCE
2020-01-15

FDA Class II Recall: Glenmark Ranitidine Tablets Pulled Nationwide Over NDMA Impurity and CGMP Deviations

Glenmark Pharmaceuticals Inc., USA initiated a nationwide Class II recall of 500,960 bottles of Ranitidine Tablets USP 300 mg due to NDMA impurity and CGMP deviations. This event, originating from its Indian manufacturing facility, necessitates immediate action from procurement and regulatory teams to reassess supplier quality and ensure robust impurity control protocols.

REGULATORY INTELLIGENCE
2020-01-15

FDA Class II Recall: Appco Pharma's Ranitidine Capsules Pulled Over NDMA Impurity and CGMP Failures

Appco Pharma LLC initiated a Class II recall of Ranitidine Capsules 300 mg due to N-nitrosodimethylamine (NDMA) impurity in the API, stemming from CGMP deviations. This event, impacting 1,632 bottles distributed across the U.S., underscores critical supply chain vulnerabilities and the imperative for robust quality control and diversified sourcing strategies for procurement and regulatory teams.

REGULATORY INTELLIGENCE
2020-01-15

FDA Scrutiny: Glenmark Ranitidine Recall Highlights Critical CGMP Deviations and NDMA Contamination

Glenmark Pharmaceuticals Inc., USA initiated a nationwide Class II recall of over 1.3 million bottles of Ranitidine Tablets USP 300 mg due to CGMP deviations and NDMA impurity. This event underscores critical supply chain and quality control risks, demanding immediate action from procurement and regulatory teams to ensure product safety and supply continuity.

REGULATORY INTELLIGENCE
2020-01-15

Idelle Labs Faces FDA Recall for Undeclared Active Ingredient in SURE Antiperspirant

Idelle Labs initiated a Class III recall for SURE 48 hr Confidence Unscented invisible solid Anti-Perspirant & Deodorant due to an undeclared active ingredient. The FDA-terminated recall, D-0783-2020, highlights critical labeling and quality control failures. This event underscores the imperative for robust supplier qualification and rigorous internal verification processes for all chemical and life science product distributors.

REGULATORY INTELLIGENCE
2020-01-08

Lupin Pharmaceuticals Recalls Bimatoprost Ophthalmic Solution Over Impurity Failures, Highlighting Supply Chain Risks

Lupin Pharmaceuticals Inc. initiated a Class III recall of 2,130 bottles of Bimatoprost Ophthalmic Solution, 0.03%, due to out-of-specification impurity levels from its Pithampur, India facility. This event underscores critical quality control vulnerabilities for procurement and regulatory teams, necessitating enhanced supplier due diligence and robust incoming material inspection protocols to mitigate supply chain disruption.

REGULATORY INTELLIGENCE
2020-01-08

Akorn's Myorisan Recall: Class II Mispackaging Exposes Critical Pharmaceutical Quality Control Gaps

Akorn, Inc. initiated a Class II recall for 4,206 boxes of MYORISAN (isotretinoin capsules, 20mg) due to unit dose mispackaging, where 40mg blister cards were found in 20mg cartons. This event, terminated in August 2022, underscores persistent quality control challenges in pharmaceutical manufacturing, impacting patient safety and supply chain integrity for procurement and regulatory leaders.

REGULATORY INTELLIGENCE
2020-01-08

FDA Class I Recall: Natures Rx's Undeclared Sildenafil in Male Enhancement Product Exposes Critical Supply Chain Risks

Natures Rx's Class I recall of "Silver Bullet, Get Bigger and Harder" due to undeclared Sildenafil and unapproved new drug status highlights severe regulatory and supply chain risks. Procurement and regulatory teams must enhance supplier vetting and product testing to mitigate exposure to adulterated products and safeguard market access and brand integrity.

CLINICAL & PIPELINE
2020-01-02

Generic Rasagiline Mesylate Approval by ALKEM LABS LTD Bolsters Parkinson's Treatment Market

ALKEM LABS LTD secured FDA approval for its generic Rasagiline Mesylate (ANDA201889) in 0.5mg and 1mg oral tablets, manufactured by Ascend Laboratories, LLC and NorthStar RxLLC. This 2017 approval, with subsequent labeling updates, significantly enhances market competition for Parkinson's disease treatment. Procurement and regulatory teams should note the expanded supply options and potential pricing shifts.

REGULATORY INTELLIGENCE
2020-01-01

Pharmedium Services Recalls Subpotent Norepinephrine Bitartrate: Critical Supply Chain Alert

Pharmedium Services, LLC initiated a nationwide Class III recall for 864 bags of subpotent NORepinephrine Bitartrate Injection. This critical "High Alert" drug, essential for cardiovascular support, posed significant patient safety risks due to compromised efficacy. Procurement and regulatory teams must scrutinize supplier quality and robust testing protocols for compounded sterile products, ensuring consistent potency for vital medicines.

ENTITY HUBS

Entities in this Brief

Sanofi-Aventis U S
company hub
Open company hub
AUBAGIO
molecule hub
Open molecule hub